1		Variants in the SOX9 transactivation middle domain induce axial
2		skeleton dysplasia and scoliosis
3		
4		Lianlei Wang ^{1,2,3#} , Zhaoyang Liu ^{4#*} , Sen Zhao ^{1,3#} , Kexin Xu ^{1,3,6#} , Valeria Aceves ⁵ , Cheng
5		Qiu ² , Benjamin Troutwine ⁵ , Lian Liu ^{1,3} , Samuel Ma ⁵ , Yuchen Niu ^{3,6,7} , Shengru Wang ^{1,3,6} ,
6	1	Suomao Yuan ² , Xiaoxin Li ^{3,6,7} , Lina Zhao ^{3,6,7} , Xinyu Liu ² , Zhihong Wu ^{3,6,7} , Terry Jianguo
7		Zhang ^{1,3,6*} , Ryan S. Gray ^{5*} , and Nan Wu ^{1,3,6*}
8		
9	1.	Department of Orthopedic Surgery, State Key Laboratory of Complex Severe and Rare
10		Diseases, Peking Union Medical College Hospital, Peking Union Medical College, and
11		Chinese Academy of Medical Sciences, Beijing, China.
12	2.	Department of Orthopedic Surgery, Qilu Hospital of Shandong University, Jinan,
13		Shandong, China.
14	3.	Beijing Key Laboratory for Genetic Research of Skeletal Deformity, Beijing, China.
15	4.	Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry,
16		University of Southern California, Los Angeles, CA, USA; Department of Nutritional
17		Sciences, Dell Pediatric Research Institute, University of Texas at Austin, Austin, TX,
18		USA.
19	5.	Department of Nutritional Sciences, Dell Pediatric Research Institute, The University of
20		Texas at Austin, Dell Medical School, Austin, TX, USA.
21	6.	Key laboratory of big data for spinal deformities, Chinese Academy of Medical Sciences,
22		Beijing, China.
23	7.	Medical Research Center, Peking Union Medical College Hospital, Peking Union Medical
24	NO	TE Aliggeprint do Gib ine ses A CA damas of Mendinal Sciences in Bailingul Abi Daused to guide clinical practice.

- 25 # These authors contributed equally to this work.
- 26
- 27 *Authors for correspondence
- 28 Nan Wu
- 29 No. 1 Shuaifuyuan, Beijing 100730, China
- 30 Phone: 86-10-69151108, dr.wunan@pumch.cn
- 31
- 32 Ryan S. Gray
- 33 1400 Barbara Jordan Blvd., Austin, TX 78723, USA
- 34 Phone: 512-495-5052, ryan.gray@austin.utexas.edu
- 35
- 36 Terry Jianguo Zhang
- 37 No. 1 Shuaifuyuan, Beijing 100730, China
- 38 Phone: 86-10-69151108, jgzhang_pumch@yahoo.com
- 39
- 40 Zhaoyang Liu
- 41 2250 Alcazar Street, Los Angeles, CA 90033, USA
- 42 Phone: 323-442-2549, liuzhaoy@usc.edu
- 43

44 Conflicts of interest

45 The authors have declared that no conflict of interest exists.

46 ABSTRACT

47 SOX9 is an essential transcriptional regulator of cartilage development and homeostasis. In humans, dysregulation of SOX9 is associated with a wide spectrum of skeletal disorders, 48 49 including campomelic and acampomelic dysplasia, and scoliosis. The mechanism of how SOX9 50 variants contribute to the spectrum of axial skeletal disorders is not well understood. Here, we 51 report four novel pathogenic variants of SOX9 identified in a large cohort of patients with 52 congenital vertebral malformations. Three of these heterozygous variants are in the HMG and 53 DIM domains, and for the first time, we report a pathogenic variant within the transactivation 54 middle (TAM) domain of SOX9. Probands with these variants exhibit variable skeletal 55 dysplasia, ranging from isolated vertebral malformation to acampomelic dysplasia. We also 56 generated a Sox9 hypomorphic mutant mouse model bearing a microdeletion within the TAM domain (Sox9^{Asp272del}). We demonstrated that disturbance of the TAM domain with missense 57 58 mutation or microdeletion results in reduced protein stability but does not affect the transcriptional activity of SOX9. Homozygous Sox9^{Asp272del} mice exhibited axial skeletal 59 60 dysplasia including kinked tails, ribcage anomalies, and scoliosis, recapitulating phenotypes 61 observed in human, while heterozygous mutants display a milder phenotype. Analysis of primary chondrocytes and the intervertebral discs in Sox9Asp272del mutant mice revealed 62 63 dysregulation of a panel of genes with major contributions of the extracellular matrix, 64 angiogenesis, and ossification-related processes. In summary, our work identified the first pathologic variant of SOX9 within the TAM domain and demonstrated that this variant is 65 66 associated with reduced SOX9 protein stability. Our finding suggests that reduced SOX9 67 stability caused by variants in the TAM domain may be responsible for the milder forms of 68 axial skeleton dysplasia in humans.

- 69 Keywords: SOX9 (SRY-Box 9), Campomelic Dysplasia, Skeletal Dysplasia, Congenital
- 70 Vertebral Malformations, Scoliosis, Protein Stability

72 INTRODUCTION

73 SRY-Box 9 (SOX9) encodes a transcriptional regulator essential for the development and 74 homeostasis of cartilaginous tissues (1). SOX9 is required to secure the commitment of 75 skeletogenic progenitor cells to the chondrocyte lineage and direct the formation of multiple 76 elements of the axial and appendicular skeleton (2). Ablation of Sox9 in mesenchymal 77 progenitors of the limb bud or during the early stages of chondrogenesis results in a complete 78 failure of cartilage and bone generation or severe chondrodysplasia (3). SOX9 is also required 79 for axial skeletogenesis. Deletion of Sox9 in the notochord prevents the formation of its 80 cartilage-rich perinotochordal sheath and results in notochordal cell death (4). Conditional 81 inactivation of Sox9 in the Scx+/Sox9+ cell populations cause severe hypoplasia of the ribcage 82 and sternum and defective formation of the vertebral bodies and intervertebral discs of the spine 83 (5). Recent studies also demonstrate that SOX9 plays a crucial role in maintaining the homeostasis of postnatal intervertebral discs (6, 7). These studies affirm that SOX9 is critical 84 85 in vertebral column development and maintenance.

86 SOX9 is featured with a highly conserved SRY-related high-mobility-group-box 87 (HMGbox) DNA-binding domain, which is found in all SOX family proteins that act as 88 transcriptional regulators in cell fate determination and differentiation in a variety of lineages 89 (2, 8). Two molecules of SOX9 can form homodimer via the self-dimerization domain (DIM) 90 upon binding in the minor groove of a DNA sequence composed of two SOX recognition motifs, 91 oriented head-to-head and separated by 3-4 nucleotides (9). In addition to the N-terminal HMG and DIM domains, SOX9 is also composed of three additional domains: the transactivation 92 93 domain in the middle of the protein (TAM), the transactivation domain at the C-terminal (TAC), 94 and the PQA (Proline, Glutamine, and Alanine-rich) domain (8). In vitro analyses show that TAM and TAC domains can work independently and synergistically to control the 95

96 transactivation of SOX9 (8). PQA domain has no major role in SOX9 transactivation but may 97 help mediate SOX9 activity in specific contexts (8, 10). The molecular functions of these C-98 terminal domains are proposed to provide synergistic binding of transcriptional co-activators 99 and basal transcriptional machinery (8). For instance, the CREB (cAMP response element-90 binding protein) transcription factor can be co-immunoprecipitated using the C-terminal 91 transactivation domains but not with the N-terminal domains of SOX9 (11).

102 Variants in SOX9 are associated with a range of skeletal deformities including campomelic 103 dysplasia (CMPD, OMIM 114290), acampomelic dysplasia (acampomelic CMPD), and 104 scoliosis (1, 12-15). Heterozygous point mutations (missense, nonsense, frameshift, and splice 105 site) in SOX9 cause CMPD, characterized by congenital shortening and bending of long bones, 106 vertebral malformation, rib anomalies, dysplasia of scapula, and dysmorphic facial features (14, 107 16-22). Heterozygous Sox9 knockout mice phenocopy most of the skeletal abnormalities of this 108 syndrome (23). Though it is generally believed that haploinsufficiency for SOX9 can underlie 109 CMPD, a recent study implicates that combined haploinsufficiency/hypomorphic and 110 dominant-negative mechanisms can apply for some SOX9 CMPD mutations in a target gene and 111 cell context-dependent manner (24). Roughly 10% of CMPD patients who do not display 112 bending of long bones are subclassified as acampomelic CMPD (25, 26). Many of the SOX9 113 variants causing CMPD are located in DIM and HMG domains, which are essential for the 114 dimerization and DNA binding properties of the SOX9 protein (19, 27) and SOX9-dependent 115 regulation of genes such as Col2a1 (28, 29) and Col11a2 (30). These patients usually exhibit 116 severe skeletal abnormalities, including deformities of the long tubular bones, and some of them 117 may present with sex reversal. CMPD can also arise from variants in the TAC and POA domains 118 of SOX9 (31, 32). Frameshift and nonsense mutations reported in these domains usually result 119 in a truncated SOX9 protein and severe CMPD and sex reversal (32, 33). On the other hand, 120 patients with acampomelic CMPD are more likely to have missense variants, genomic

121 rearrangement with breakpoints upstream of SOX9, or a SOX9 upstream deletion (34). We have 122 previously identified a recurrent missense variant at the prolines/glutamines/serines (PQS) 123 domain (now called TAC domain) of SOX9 in patients with congenital vertebral malformations 124 but without other systematic deformities (35), which is one of the first non-truncating variants reported in the TAC domain that is associated with a milder form of axial skeleton dysplasia. 125 No missense or nonsense variant in the TAM (previously called K2) domain has been reported 126 127 so far (36, 37). These observations suggest that locations of variants in different domains of 128 SOX9 might underline a spectrum of skeletal dysplasia from CMPD to milder forms that 129 primarily or exclusively affect the axial skeleton.


130 To this end, we investigated ultra-rare SOX9 variants within a large cohort of congenital vertebral malformations and identified four novel variants of SOX9. We report the first 131 132 pathologic missense variant of SOX9 within the TAM domain associated with a milder form of axial skeletal dysplasia and demonstrated that variants in the TAM domains result in reduced 133 134 SOX9 protein stability. We also generated a Sox9 hypomorphic mouse model with in-frame 135 microdeletion in the TAM domain which recapitulates some of the skeletal phenotypes 136 observed in the human patient. This work enhances our understanding of SOX9 function in the axial skeleton and provides new insights into the roles of different SOX9 domains in the 137 138 spectrum of skeletal dysplasia.

139 **RESULTS**

140 Rare and *de novo SOX9* variants identified in individuals with various severity of skeletal 141 dysplasia

142 We investigated ultra-rare SOX9 variants with a cohort of 424 patients of congenital vertebral malformations, which consists of a broad spectrum of syndromic and non-syndromic vertebral 143 144 deformities. Four novel heterozygous missense variants were identified from four probands, 145 including three de novo variants (c.218T>C, p.Ile73Thr; c.337A>C, p.Met113Leu and c.826G>T, p.Gly276Cys) and one variant (c.398C>G, p.Ala133Gly) with unknown inheritance 146 147 (Figure 1, A and B, and Table 1). The clinical and genetic features of these probands are 148 summarized in Table 1. No pathogenic variants in other genes were identified. Family history 149 assessments of the probands show that their parents and siblings are all uneventful.

150 Two of the four probands RDD2003P0397 (Figure 1B) and SCO2003P0412 (Figure 1C) 151 exhibited deformities consistent with the clinical manifestations of acampomelic CMPD. RDD2003P0397 presented congenital vertebral malformation caused by the fusion of the 152 153 cervical vertebra (Figure 1B). Exome sequencing identified a de novo heterozygous missense 154 variant c.337A>C (p.Met113Leu) located within the HMG-box of SOX9 (Figure 1A). Two 155 missense variants (Met113Thr and Met113Val) that affect the same amino acid have been 156 reported previously in a CMPD patient (Met113Thr) and an acampomelic CMPD patient (Met113Val), respectively (38, 39). SCO2003P0412 presented congenital kyphosis (Figure 157 158 1C). He had a heterozygous missense variant (c.398C>G, p.Ala133Gly) within the HMG-box of SOX9 with an unknown inheritance origin (Figure 1C). No pathogenic variant of this amino 159 160 acid has been reported previously. Notably, Ala133Gly is predicted to be highly deleterious 161 (combined annotation dependent depletion [CADD] score = 24.1).



Both the Asp272 and Gly276 variants are highly conserved residues. *CMPD: Campomelic Dysplasia; acampomelic CMPD: Acampomelic Dysplasia; DIM: dimerization domain; HMG: high mobility group domain; TAM: transactivation middle, PQA: proline, glutamine, and alanine-rich domain; TAC: transactivation C- terminal.*

173

163

164

165

166

167

168

In contrast to these two cases diagnosed as acampomelic CMPD, the third proband SCO2003P0060 presented a milder skeletal dysplasia phenotype characterized by a wedged vertebra at T6 and thoracic scoliosis (Figure 1D). She also presented with short stature and kyphoscoliosis (Table 1). She carried a *de novo* variant c.218T>C (Ile73Thr) located in the DIM domain of *SOX9* (Figure 1A). A variant affecting the same amino acid (Ile73Asn) has
been reported previously in a patient with multiple congenital anomalies (40). This c.218T>C
(Ile73Thr) variant has not been included in the gnomAD (v2.1.1, https://gnomad.
broadinstitute.org, accessed on January 5, 2023), and it is classified as likely pathogenic
(PM2_Supporting + PS3_Supporting + PS2 + PM5_Supporting) according to the ACMG
guideline (41).

In the fourth proband (SCO2003P1898), we identified a de novo variant c.826G>T 184 185 (Gly276Cys) located at the TAM domain (8) of SOX9 (Figure 1A). This Gly276 residual is highly conserved among vertebrate orthologues (Figure 1G). To our knowledge, this is the first 186 187 missense mutation reported within the TAM domain in humans. This proband exhibited fused 188 vertebrae from T6-T11 and spinal bifida occulta of L4-L5 (Figure 1E). She also exhibited thoracic scoliosis and clinodactyly of the distal 5th phalange (Figure 1E). Interestingly, the 189 190 multiple fusion of thoracic vertebrae phenotype in this proband was distinct from the other three patients and the classical CMPD/ acampomelic CMPD patients, suggesting that variants 191 192 in the TAM domain of SOX9 may be associated with a distinct type of skeletal anomalies.

193 To further characterize the impact of *SOX9* variants, we modeled the potential structural 194 effects of these mutations predicted by Alpha Fold (Supplemental Figure 1,

195 https://alphafold.ebi.ac.uk) (42). The evolutionally conserved SOX9 Ile73, Met113, and Ala133 196 residues are predicted to help stabilize alpha-helical regions (Supplemental Figure 1, B-D) 197 within the regions with high confidence of prediction or within areas where structural 198 information was empirically determined (unpublished PDB data: 4EUW and 4S2Q). The 199 highly conserved SOX9 Gly276 residue (Fig. 1G) is predicted to hydrogen bond interact with 200 Asp274 (Supplemental Figure 1E) in a putative helical region of the protein. Altogether, the in 201 silico evidence showed that the affected residues are highly conserved among vertebrate 202 orthologues, and alteration of these residues may lead to compromised protein structure and

altered interactions with other residues, which may jeopardize the function and structuralstability of the SOX9 protein.

205 Effects of the SOX9 variants on DNA-binding and transcriptional activities of SOX9

- 206 Next, we sought to understand how *SOX9* variants affect the DNA-binding and transcriptional
- 207 activities of the SOX9 protein using electrophoretic mobility shift assay (EMSA) and luciferase
- 208 reporter assay. We synthesized two sets of EMSA probes derived from the enhancer region of
- the mouse *Coll1a2* gene (30). Each probe contains a canonical SOX9 DNA-binding motif and
- 210 was named *Coll1a2* B/C and *Coll1a2* D/E respectively. An equal amount of SOX9 wild-type
- and variants proteins were incubated with these probe sets for EMSA analyses (Supplemental
- Figure 2). We discovered that both SOX9 variants within the HMG-box (Met113Leu and
- 213 Ala133Gly) display impaired DNA-binding

220




Figure 2. Effects of the *SOX9* **variants on DNA-binding and transcriptional activities of SOX9. (A)** Electrophoretic mobility shift assay (EMSA) was performed on the whole cell lysate extracted from Cos-7 cells. Cell lysate with no transfection was used as a blank control (Blank). Cos-7 cells transfected with a GFP control construct were used as a mock control (Control). The 150-fold unlabeled DNA probes (150X) were incubated with cell lysate of Cos-7 cells transfected with wild-type SOX9 protein. Free probes were detected at the bottom of the gel.

226 The bound dimer and monomer SOX9 proteins are indicated with black and red arrows, respectively. (B)

- 227 Luciferase assay was performed on wild-type (WT) SOX9 protein and various SOX9 variant mutant proteins
- 228 using a Coll1a2-Luc construct. His165Tyr variant protein was used as a negative control (31). The statistical
- 229 difference is evaluated by one-way ANOVA followed by Tukey's multiple comparison test. The data are the mean
- 230 of n = 3 independent experiments. Error bars show one standard deviation. * p < 0.05 ** p < 0.01 ns: not
- 231 significant.


232 capability characterized by decreased probe binding signal (Figure 2A, black arrows). The 233 SOX9 variant within the DIM domain (Ile73Thr), which is an essential domain for the 234 dimerization of SOX9 proteins (43), showed reduced DNA-binding capability and loss of 235 dimerization (Figure 2A, black arrows, and red arrows). To define if these variants affected SOX9-dependent gene transcription, we co-transfected various SOX9-expression vectors with 236 a luciferase reporter construct (named Coll1a2-Luc) which contains 4 tandem copies of the 237 238 canonical SOX9 DNA-binding motif Coll1a2 D/E (Supplemental Figure 3 and Supplemental 239 Table 2) (30, 44). We showed that both the HMG-box variants (Met113Leu and Ala133Gly) 240 and the DIM domain variant (Ile73Thr) exhibited decreased transcriptional activity of SOX9 241 (Figure 2B). In contrast, the variant in the TAM domain (Gly276Cys) did not obviously 242 compromise the transcriptional activity of SOX9 compared with the wild-type protein but 243 showed significantly higher transcriptional activity compared with the Ile73Thr, Met113Leu, 244 and Ala133Gly variants (Figure 2B). Taken together, these data suggest that the variants in 245 HMG and DIM domains are likely affecting the DNA-binding capabilities and homotypic interactions of SOX9, which may lead to compromised SOX9-dependent transcriptional 246 247 activities. In contrast, variants in the TAM domain may still allow for some transcriptional 248 activity at the canonical SOX9 targets thus permitting partial SOX9-dependent function.

249 A TAM domain mutation in mice leads to dose-dependent reductions of SOX9

250 expression and tail kinking during perinatal development

251 To further our understanding of the role of the TAM domain variant in skeletal dysplasia, we 252 set out to use a CRISPR-Cas9 gene-editing approach to knock in the human variant Gly276Cys 253 in the mouse (Figure 1E). After multiple injections, we isolated only three CRISPR-injected 254 mice as adults (0.3%; n=123 implanted), likely due to haploinsufficient lethality of Sox9 in the mouse (23). Serendipitously, we obtained an in-frame microdeletion allele (Sox9^{em1Rgray}), 255 256 which deleted Asp272 (Asp272del), four amino acids upstream of Gly276Cys within the TAM 257 domain (Figure 1A, Figure 3, A and N). Like the Gly276 residual, the Asp272 residual is also 258 highly conserved among vertebrate orthologues (Figure 1G) and is predicted to hydrogen bond 259 interact with Asp274 by Alpha Fold structural prediction (Supplemental Figure 1E). Intercross of these Sox9^{Asp272del/+} mice (hereafter called Sox9^{del}) generated Sox9^{del/del} mutant mice at 260 261 Mendelian ratios that are indistinguishable from the $Sox9^{del/+}$ or wild-type ($Sox9^{+/+}$) littermates at birth. However, by postnatal (P) day 5 Sox9^{del/del} mutant mice exhibited a fully penetrant 262 263 kinked tail phenotype (100%, n=12) (Figure 3D, red arrow). In contrast, heterozygous Sox9^{del/+} and wild-type littermates uniformly displayed normal tails (Figure 3, B and C). 264

265



255

Figure 3. A TAM domain mutation in mice leads to dose-dependent reductions of SOX9 expression and tail kinking during perinatal development. (A) Illustration of the in-frame deletion of Asp272 in the $Sox9^{del/del}$ mutant mouse. The red arrow indicates the Asp272del mutation. (B-D) At P5, an obvious kinked tail phenotype was observed in 100% of the $Sox9^{del/del}$ mutant mice, but not in heterozygous $Sox9^{del/+}$ or wild-type littermates.

260	(n=12 for <i>Sox9^{del/del}</i> mice, n=8 for <i>Sox9^{del/+}</i> and wild-type littermates). (E-G''') Alcian Blue Hematoxylin /Orange
261	G (ABH/OG) staining performed on P5 mouse tail sections revealed normal segmentation of the vertebral bodies
262	and typical proteoglycan staining of IVD and growth plate in Sox9 ^{del/del} mutant mice (G) compared with the
263	wildtype (E) and Sox9 ^{del/+} (F) littermates. Red and pink arrowheads indicate wedged and unwedged IVDs in
264	Sox9 ^{del/del} mutant mouse, respectively. Higher magnification images of the endplate and growth plate and the
265	annulus fibrosus are shown in (E'-G') and (E''-G'''). The endplate is indicated with a dotted line and a vertical
266	bar in (E'G'). The boundary between inner and outer annulus fibrosus is indicated with a dotted line in (E''-G''').
267	(n=4 for each genotype). (H-J'') Immunohistochemistry (IHC) analyses of SOX9 performed on P5 mouse tail
268	sections. Higher magnification images of the endplate and growth plate and the annulus fibrosus are shown in
269	(H'-J') and (H''-J'''). The endplate is indicated with a dotted line and a vertical bar in (H'-J'). SOX9 expression
270	in proliferative growth plates is indicated with red arrows in (H') and (I'). The boundary between inner and outer
271	annulus fibrosus is indicted with a dot-line in (H''-J'''). The absence of SOX9 expression in the outer annulus
272	fibrosus is indicated with red arrows in (J'') and (J'''). (n=4 for each genotype.) (K-M) Immunofluorescence (IF)
273	analyses of SOX9 were performed on P5 mouse tail sections. (n=6 for each genotype.) (N) Sanger sequencing
274	results of wild-type, Sox9 ^{del/+,} and Sox9 ^{del/del} mice. The red arrow indicates the Asp272del mutation. (O-T)
275	Quantification of the number of cell layers in endplate (O), and quantification of the percentile of SOX9 (+) cells
276	in endplate (P), proliferative growth plate (Q), hypertrophic growth plate (R), inner annulus fibrosus (S), and
277	outer annulus fibrosus (T) in three genotypes of mice. Bars are plotted with mean and 95%CI. Each dot represents
278	one mouse analyzed. The statistical difference is evaluated by one-way ANOVA followed by Tukey's multiple
279	comparison test. * p<0.05, **: p<0.01, ***p<0.001. ns: not significant. For (O), n=5 for each genotype; for (PT),
280	n=3 for each genotype. Scale bars: 10mm in B ; 100µm in E-E''' , H-H''' and K . VB: vertebral body; AF: annulus
281	fibrosus; EP: endplate; GP: growth plate; NP: nucleus pulposus; GP-p: proliferative growth plate; GPh:
282	hypertrophic growth plate; AF-i: inner annulus fibrosus; AF-o: outer annulus fibrosus.

283

284 Many congenital vertebral malformations are due to patterning defects of embryonic 285 somites which contribute to the formation of vertebral bodies and intervertebral discs (IVDs) (45). Histological analysis of Sox9^{del/del} mutant mouse tails at P5 revealed normal segmentation 286 and ossification of the vertebral bodies and typical proteoglycan staining in the IVDs and growth 287 plates (Figure 3, E-G). However, the Sox9^{del/del} mice showed wedging of the IVDs in regions of 288 289 tail kinking, a shift of the nucleus pulposus toward the convex side (Figure 3G, red arrowheads), 290 and compression of annulus fibrosus on the concave side of the curvature (Figure 3G'''). In 291 contrast, unwedged IVDs adjacent to severe curvatures could display comparably normal 292 structures (Figure 3G, pink arrowhead, and Supplemental Figure 4A). Detailed analysis of the

tail sections revealed that the thickness of the cartilaginous endplate of the IVDs is reduced in Sox9^{del/+} and the Sox9^{del/del} mutant mice compared with that of the wild-type mice (Figure 3, E' and G', yellow bars) quantified by the number of cell layers within the endplate (Figure 3O). The number of endplate cell layers in the unwedged IVDs of the Sox9^{del/del} mutant mice is slightly increased compared with that of the wedged IVDs but is still reduced in comparison with the wild-type mice (Figure 3O and Supplemental Figure 4A').


We next sought to determine how SOX9 expression was affected in Sox9^{del/del} mutant 299 300 tissues. Immunohistochemistry (IHC) and immunofluorescence (IF) analyses of P5 tail sections revealed that SOX9 expression is regionally reduced in the Sox9^{del/+} and the Sox9^{del/del} mutant 301 mice (Figure 3, H-J' and K-M). We observed a decreased SOX9 expression in the proliferative 302 303 growth plate adjacent to the wedged IVDs but not the unwedged IVDs of the Sox9^{del/del} mutant mice (Figure 3, H'-J' and Q, and Supplemental Figure 4, B-B'). No difference in SOX9 304 305 expression was observed in the hypertrophic growth plate (Figure 3, H'-J' and R) nor the 306 endplate (Figure 3P) among the three genotypes. We also observed reduced expression of SOX9 in both inner and outer layers of the annulus fibrosus of the Sox9^{del/del} mutant mice in 307 308 both wedged and unwedged IVDs (Figure 3, H"-H" and 3S-T, and Supplemental Figure 4B"), with more pronounced effects on the outer layers (Figure 3, J"-J", red arrows; and 309 Figure 3T), as well as decreased SOX9 expression in the outer annulus fibrous of the Sox9^{del/+} 310 311 mice (Figure 3T). IHC analyses of type II collagen (COLII) and type X collagen (COLX) 312 showed a comparable pattern of staining at this age among all three genotypes (Supplemental 313 Figure 4, C-H). All these results suggest that the mutation in the TAM domain leads to a dose-314 dependent mild reduction of SOX9 expression in various compartments of the spinal tissues, 315 associated with a tail kinking phenotype during perinatal development. However, the overall 316 patterning and segmentation of the vertebral bodies are not affected.

317 *Sox9*^{Asp272del} is a hypomorphic loss-of-function allele

The tail kinking phenotype and the reduced SOX9 expression in the Sox9^{del/+} and the Sox9^{del/del} 318 mutant mice are dose-dependent and region-specific, suggesting that the Asp272del 319 320 microdeletion was behaving as a mild hypomorphic allele of Sox9. To test the nature of the 321 Sox9^{del} allele, we assessed how skeletal development would be affected when the Sox9^{del} allele was *in trans* with an established floxed null allele of Sox9 ($Sox9^{flox}$) (3). Previous studies show 322 323 that completely inactivating Sox9 in osteochondral progenitors using the Col2al-Cre deleter 324 strain (*Col2a1-Cre;Sox9^{flox/flox}*) resulted in embryonic lethality and severe chondrodysplasia in mutant embryos, while the heterozygous recombination of Sox9 (Col2a1-Cre; Sox9^{flox/+}) caused 325 326 perinatal lethality around P10 displaying dwarfism and kyphosis of the axial skeleton (3). Given these findings, we set out to assess skeletogenesis of the Col2al-Cre;Sox9flox/del 327 compound heterozygous mutants in comparison with the *Col2a1-Cre;Sox9^{flox/+}* heterozygous 328 329 mutants at P1.

The Col2a1-Cre; Sox9^{flox/del} compound heterozygous mice were born at Mendelian ratio 330 331 (n=8; total 67 pups) with a 63% survival rate at P1. Skeletal preparations showed increased 332 defects of craniofacial and ribcage development and bending of the long bone in the Col2a1-Cre; Sox9^{flox/del} compound heterozygous mutants compared with the Col2al-Cre; Sox9^{flox/+} 333 heterozygous littermates (Supplemental Figure 5, B and C). To better quantify skeletal 334 335 phenotypes, we analyzed the skull morphology with MicroCT imaging (Figure 4 and 336 Supplemental Figure 5, D-F). We observed decreased skull size in Col2al-Cre;Sox9^{flox/del} 337 compound heterozygous mutants (Figure 4, C-D) compared with Cre (-) controls (Figure 4, A and A') and Col2al-Cre; Sox9^{flox/+} heterozygous mutants (Figure 4, B and B'). However, we 338 339 observed no significant change in the percentage of bone volume when normalized to total 340 tissue volume (BV/TV) (Figure 4E), which is consistent with the previous report that Sox9 341 deletion does not obviously affect osteoblast differentiation (3). Taken together, these genetic

- 342 studies provide functional evidence that the *Sox9*^{*del*} allele, which disturbs the TAM domain of
- 343 *SOX9*, is acting as a mild hypomorphic allele.



346 Figure 4. Sox9Asp272del is a hypomorphic loss-of-function allele. (A-C'), 3D MicroCT renderings of mouse skulls 347 from Cre(-) control (A, A'), Col2al-Cre; Sox9^{flox/+} (B, B'), and Col2al-Cre; Sox9^{flox/del} mutant (C, C') mice at P1 348 in lateral (A-C) or dorsal views (A'-C'). (D) Quantification of bone surface area (μm^2) of the skull shows a 349 reduced skull size of the Col2a1-Cre; Sox9^{flox/del} compound heterozygous mutant mice (p= 0.0428) compared to 350 wild-type Cre(-) control mice. (E) Quantification of the percentage of bone volume vs tissue volume (BV/TV) 351 shows no loss of bone mass density in the skulls of Col2al-Cre; Sox9^{flox/del} mutant mice (p=0.2972) compared to 352 wild-type Cre(-) control mice. Bars are plotted with mean and standard deviation. Each dot represents one mouse 353 analyzed. The statistical difference is evaluated by one-way ANOVA followed by Tukey's multiple comparison 354 test. n=4 for each genotype. Scale bars 1mm.

355 Disturbance of the TAM domain of SOX9 results in dose-dependent skeletal dysplasia in

356 young adult mice


345

357 By postnatal (P) day 60 (P60), Sox9^{del/del} mutant mice are adult-viable (Figure 5C). Dorsal X-358 ray imaging showed normal segmentation and growth of the spine irrespective of genotype (Figure 5, C-D). However, Sox9^{del/del} mutant mice did display shorter femurs compared with 359 Sox9^{del/+} and the wild-type mice (Figure 5D). We observed loss of the thoracic (T) 13 floating 360 ribs (100%, n=18; 8 male, 10 female) in Sox9^{del/del} mice (Figure 5C', red asterisks; and Figure 361 4E), with the majority of Sox9^{del/del} mice (94%) displaying bilateral loss of the T13 floating ribs 362 (Figure 5E). Notably, 16% of heterozygous Sox9^{del/+} mice (n=25, 15 males, 10 females) also 363 displayed loss of either the right or left T13 floating rib (Figure 5C', red asterisk; and Figure 364 5E). In contrast, we never observed the loss of the T13 floating ribs in wild-type mice (n=8, 4 365 males, 4 females) (Figure 5, A' and E). Sagittal X-ray imaging showed that 43% of Sox9^{del/del} 366

mutant mice (n=7, 4 males, 3 females) showed ribcage defects at P60, which was not observed in wildtype (n=4, 2 males, 2 females) or $Sox9^{del/+}$ mice (n=8, 5 males, 3 females) (Supplemental Figure 6). Altogether, these results show that an in-frame microdeletion within the TAM domain of SOX9 causes spatially restrictive disruptions in the development of the axial and appendicular skeleton, some of which are hallmarks of acampomelic CMPD including loss of ribs, ribcage defects, and shortened long bones (14, 16).

Sox9^{del/del} mutant mice also displayed an exacerbated kinked tail phenotype at P60 (Figure 373 374 5H). MicroCT imaging showed that tail kinks are associated with dysmorphic coccygeal vertebrae (Figure 5, H-H""), including ectopic bone deposition in the marrow space in 375 Sox9^{del/del} mutant mice, bending of the vertebra, and fusion between vertebrae (Figure 5, H'-376 377 H" and I). The bending and fusion of the caudal vertebrae in the Sox9^{del/del} mice mimicked 378 some phenotypes observed in the human patient with the Gly276Cys mutation (Figure 1E). Histological analysis of these kinked tail regions in Sox9^{del/del} mice showed severe dysplasia of 379 380 IVDs and growth plate (Figure 5, L-L'). In some regions, the nucleus pulposus was pushed 381 toward the convex side of the curve, embedded within the annulus fibrosus layers (Figure 5L, yellow arrow). Some Sox9^{del/del} mice also showed thinning and disruption of IVD endplate, 382 383 characterized by loss of cellularity and lack of ossification in the endplate (Figure 5L') compared with the normal structure observed in wild-type and Sox9^{del/+} mice (Figure 5, J-J' 384 385 and K-K'). The vertebral growth plate within the kinked tail region is also disrupted, with disorganized cell columns and reduced proteoglycan staining in some regions of the growth 386 387 plate (Figure 5L'), consistent with the reported reduction in proteoglycan staining in the IVDs 388 of conditional SOX9 loss-of-function mice (6), further supporting our model that Sox9^{del} allele 389 behaves as a mild hypomorphic allele. These results demonstrate that a microdeletion variant 390 in the TAM domain of SOX9 is sufficient to cause the progressive onset of skeletal dysplasia

- 391 characterized by gross histological pathology of the IVDs, bending of the vertebral bodies, and
- 392 pathological changes of the growth plate.



393

394 Figure 5. Variants in the TAM domain of SOX9 results in a dose-dependent skeletal dysplasia in adult 395 mouse. (A-C') Dorsal X-ray images of wild-type (A, A'), Sox9^{del/+} (B, B'), and Sox9^{del/del} mutant mice (C, C') at 396 P60. The presence and loss of T13 floating ribs are indicated with red arrows and red asterisks, respectively. (D) 397 Measurements of the length of the spine (T1-L6) and the long bone (femur) in P60 mice. Bars are plotted with 398 mean and 95%CI. Each dot represents one mouse analyzed. Male animals are marked with blue dots and female 399 animals are marked with pink dots. The statistical analysis is one-way ANOVA followed by Tukey's multiple 400 comparison test. ***p<0.001. ns: not significant. (n=6 for wild-type mice; 3 males, 3 females. n=8 for Sox9^{del/+} 401 mice; 4 males, 4 females. n=6 for Sox9del/del mice; 3 males, 3 females). (E) Quantification of the floating rib 402 phenotype in P60 mice. (n=12 for wild-type mice; 7 males, 5 females. n=25 for Sox9^{del/+} mice; 15 males, 10 females. n=18 for Sox9^{del/del} mice; 8 males, 10 females). (F-H) MicroCT analyses showing 3D reconstruction of 403

404 the straight tails in wild-type (F) and Sox9^{del/+} (G) mice, but kinked tail in Sox9^{del/del} mice (H) at P60. Demonstrates 405 a dose-dependent increase in attenuating bony matrix deposition in the bone marrow space in the optical sections 406 of Sox9del/+ and Sox9del/del mutant mice (lower panels: G'-G''' and H'-H''' respectively). (I) Analysis of percent 407 bone volume (BV)/tissue volume (TV) of the 5-7th coccygeal vertebrae counting from the distal-most tip of the tail showing significant increase in BV/TV (%) in Sox9^{del/del} mutant mice (p=<0.0001) compared with wild-ype 408 409 control mice. Bars are plotted with mean and SEM. Each dot represents one coccygeal vertebra analyzed. The 410 statistical difference is evaluated by one-way ANOVA followed by Tukey's multiple comparison test. n=4 mice 411 for each genotype. (J-L') ABH/OG staining performed on tail sections of P60 wild-type (I, I'), Sox9^{del/+} (J, J'), and Sox9^{del/del} (K, K') mice showed severe disruption of IVD in Sox9^{del/del} mice tails. The yellow arrow indicates 412 413 nucleus pulposus tissue into the annulus fibrosus layer and a yellow asterisk indicates disorganization of the 414 annulus fibrosus. n=3 for each genotype. Scale bars: 10mm in A; 5mm in A'; 2mm in F; and 100µm in I-I'. AF: 415 annulus fibrosus; EP: endplate; GP: growth plate; NP: nucleus pulposus.

416 Disturbance of the TAM domain of SOX9 leads to late-onset scoliosis in mouse

417 We consistently observed skeletal dysplasia in the tails of $Sox9^{del/del}$ mutant mice from P5 to


418 P60 but we never observed obvious dysplasia in the thoracic or lumber spine at this time

419 (Figure 5, A-C). However, when we assessed these mutants at 6 month-of-age, $\sim 43\%$ of Sox9^{del/del} mutant mice (n=14, 8 males, 6 females) displayed mild lateral curvature of the spine 420 421 reminiscent of late-onset scoliosis (Figure 6, C and F). The severity of spine curvatures, 422 quantified as Cobb angles (46), ranged from 10.2° to 13.8° (Figure 6I). We observed scoliosis 423 in both male and female Sox9^{del/del} mutant mice with curvatures in both rightward and leftward directions (Figure 6I). The distribution of the apex of the curvature was enriched in the lower 424 425 thoracic region (T12-T13) and lumbar region (L1, L4, and L5) (Figure 6J). In comparison, only one female Sox9^{del/+} mouse (n=15, 12 males, 3 females) showed a mild curve of 10.7° at 6 426 months (Figure 6H), while the majority of $Sox9^{del/+}$ mice and all of the wild-type mice (n=8, 4 427

428 males and 4 females) had no measurable scoliosis at 6 months (Figure 6G).


In addition, we also observed a range of rib cage deformities in 93% of the $Sox9^{del/del}$ mice at 6 months (n=14, 8 males, 6 females), from obvious dorsal ward bending of the sternums into the rib cage akin to pectus excavatum in humans (47) (Figure 6F'), to milder bending of the

432 sternums (Supplemental Figure 7, C and D) and curvatures of the distal ribs (Supplemental Figure 7E). We only observed 1 male $Sox9^{del/+}$ mice displaying mild bending of the sternum at 433 434 6 months (n=8, 4 males and 4 females) (Supplemental Figure 7B). In contrast, none of the wild-435 type littermates displayed rib cage deformities (n=8, 4 males and 4 females) (Figure 6D'). The 436 etiology of pectus excavatum is still not clear, but it may be associated with genetic or 437 connective tissue disease that leads to compromised support of the rig cage (48). These results suggest that disturbance of the TAM domain of SOX9 also affects the stability of the axial 438 439 skeleton during adult development, modeling late-onset scoliosis and progressive rib cage 440 deformities in a dose-dependent manner, potentially through regulating the homeostasis of 441 cartilaginous and connective tissues in the spine and rib cage.





------ 6 months ------



454 F' indicates rib cage deformity. (n=8 for wild-type mice; 4 males, 4 females. n=15 for Sox9^{del/+} mice; 12 males, 3 455 females. n=14 for Sox9del/del mice; 8 males, 6 females.) (G-I) Cobb angle measurements of wild-type (G), Sox9del/+ 456 (H) and $Sox_{9^{del/del}}$ (I) mice at 6 months. Areas of scoliosis (Cobb angle >10 degrees) are indicated with two red 457 dot lines. (J) Heat map of the apex distribution of the scoliotic Sox9^{del/del} mutant mice at 6 months. The heat map 458 is plotted with the axis level of the thoracic spine (T8-L6) and the number of scoliotic mice with apex observed at 459 each level. (n=8 for wild-type mice; 4 males, 4 females. n=15 for Sox9^{del/+} mice; 12 males, 3 females. n=14 for 460 Sox9del/del mice; 8 males, 6 females.) (K-M'), ABH/OG staining performed on lumbar IVDs (L4/5) of 6-monthold wild-type (K, K'), Sox9^{del/+} (L, L') and Sox9^{del/del} (M, M') mice. The endplate and growth plate are indicated 461 462 with black and yellow asterisks, respectively. Endplate clefts observed in $Sox 9^{del/del}$ mice are indicated with a red 463 arrow in (M') (n=3 for each genotype.) (N-S), Immunohistochemistry (IHC) analyses of type X collagen (COLX) and type II collagen (COLII) in 6-month-old wild-type (N, N' and Q), Sox9^{del/+} (O, O' and R) and Sox9^{del/del} (P, 464 465 P' and S) mice. Endplate staining and growth plate staining are indicated with red and vellow asterisks, 466 respectively. n=6 for each genotype. Scale bars: 10mm in A, D, and D'; 100um in K-K', N-N', and O. EP: 467 endplate; GP: growth plate; NP: nucleus pulposus.

468

469 Adult *Sox9*^{del/del} mutant mice display IVD defects of the spine


470 SOX9 function is required in adult mice to maintain homeostasis of the cartilaginous tissues (6, 49). To determine if Sox9^{del/del} mutant mice might accumulate increased pathology of 471 472 skeletal elements in older mice we looked at 6-month-old cohorts. We observed endplate defects in 50% (n=6) of Sox9^{del/del} mutant mice (Figure 6, M-M'), characterized by vertical cleft 473 474 through endplate into growth plate in the lumbar IVDs (Figure 6M', red arrow), which was not observed in Sox9^{del/+} or wild-type littermates (n=6 for each genotype) (Figure 6, K-L'). We also 475 476 observed reduced proteoglycan staining in some growth plates of the lumbar spine in the Sox9^{del/del} mice (Figure 6M', yellow asterisk). 477

The endplates of the lumbar IVDs undergo ossification in wild-type adult mice (Figure 6, K' and 6L', black asterisks, and Supplemental Figure 7, F-G'). Interestingly, the *Sox9^{del/del}* mice consistently displayed a reduction in endplate ossification in lumbar regions (Figure 6M' and Supplemental Figure 7J'), which was associated with an accumulation of COLX (+), hypertrophic chondrocyte-like cells in the endplate (Figure 6P', red asterisk; Figure 6M', black

483 asterisk, and Supplemental Figure 7, H' and I'). COLX is a biomarker of IVD degeneration 484 (50, 51). We also observed increased COLX expression enriched around the endplate cleft and in the growth plate and nucleus pulposus of the Sox9^{del/del} mice (Figure 6, P-P'), which suggests 485 486 that reduction in SOX9 function is eliciting degenerative changes in the IVD. The ossification of the endplate in wild-type and Sox9^{del/+} mice was also correlated with a reduction of COLII 487 expression in the endplate (Figure 6, Q and R, red asterisks), however, COLII staining was 488 increased in Sox9^{del/del} mutant endplate (Figure 6S, red asterisks). The persistent expression of 489 490 both COLII (Figure 6S) and COLX (Figure 6P') in large, hypertrophic chondrocyte-like cells 491 in the endplate suggests that the TAM domain of SOX9 is important for pathways involved in 492 chondrocyte maturation in the lumbar spine.

493 Variants of the TAM domain decrease SOX9 protein stability and chondrogenesis in cell 494 culture

495 Next, we sought to determine how disturbance of the TAM domain affects SOX9 function. 496 Consistent with our previous results with the human Gly276Cys SOX9 TAM domain variant 497 (Figure 2B), the luciferase assay showed that the Asp272del variant of SOX9 showed no 498 obvious change in transcriptional activity compared with the wild-type protein or the 499 Gly276Cys variant (Figure 2B). Previous studies reported that phosphorylation of the TAM 500 domain helps regulate SOX9 stability in response to DNA damage in cancer cells (52). We next 501 sought to assay SOX9 protein stability by measuring the half-life of different SOX9 variants in 502 Cos-7 cell culture after treatment with cycloheximide (CHX), which blocks de novo protein 503 synthesis (53). Quantification of SOX9 revealed that the half-life of wild-type SOX9 was ~4 504 hours after CHX treatment, while the half-lives of both the human Gly276Cys and the mouse 505 Asp272del variant of SOX9 proteins were reduced to ~2.5 hours (Figure 7, A and B, n=3).



507 508

Figure 7. Variants of the TAM domain leads to reduced protein stability of SOX9 and impaired 509 chondrogenesis in cell culture. (A-B) Representative Western blot assay of SOX9 half-life measurements (A). 510 Cos-7 cells were transfected with plasmids expressing wild-type SOX9, the Asp272del variant, or the Gly276Cys 511 variant for 48 hours, followed by cycloheximide (CHX) treatment (80 µg/ml) for 0h, 1h, 2h, 4h, and 6h. Total 512 protein was harvested at each time point and blotted with SOX9. GAPDH was used as a loading control. 513 Quantification of band intensity was shown in (B). (n=3 experiments.) (C-D), Alcian Blue staining (C) on costal chondrocytes isolated from P5 wild-type, Sox9^{del/+}, and Sox9^{del/del} mice that were maturated for 10 days. The 514

515 number of nodules formed per tissue-culture well was quantified in (D). (n=3 experiments.) (E), Real-time RT-516 PCR analyses of Sox9, Col2a1, Acan, and Col10a1 on RNA isolated from P5 primary costal chondrocytes of three 517 different genotypes. Bars are plotted with mean and 95%CI. Three pups of each genotype were pooled to generate 518 a sample. Three technique replicas were applied for each experiment. The statistical difference is evaluated by 519 one-way ANOVA followed by Tukey's multiple comparison test. * p<0.05, **: p<0.01, ***p<0.001. 520 ***p<0.0001. ns: not significant. (F), Immunofluorescence (IF) analyses of SOX9 performed on P5 primary costal 521 chondrocytes of three different genotypes revealed comparable expression levels and normal nuclei localization 522 of the SOX9 Asp272del variant protein. (n=3 experiments.) Scale bars: 500µm in C; 50µm in F.

Given the pathology of cartilaginous tissues in the IVD in Sox9^{del/del} mutant mice, we next 523 524 sought to test if primary costal chondrocytes would also model these defects in vitro. Alcian Blue staining on maturated primary costal chondrocytes revealed weaker Alcian Blue staining 525 and a reduction in cartilage nodules formation of chondrocytes derived from both Sox9^{del/+} and 526 Sox9^{del/del} mice compared with that derived from wild-type littermates (Figure 7, C and D), 527 528 suggesting diminished chondrogenesis in vitro (54) with the Asp272del TAM domain variant of SOX9. This observation is confirmed by the reduced expression of Acan (Figure. 7E), which 529 530 encodes the major chondroitin sulfate proteoglycan aggrecan and its deposition is considered a 531 hallmark of chondrogenesis (55). In agreement with our observations of increased COLX expression in cartilaginous endplate in Sox9^{del/del} mutant mice (Figure 6, P-P'), we also observed 532 increased Coll0a1 expression in primary costal chondrocyte culture in both Sox9^{del/+} and 533 534 Sox9^{del/del} mice (Figure 7E). These findings indicate that the Asp272del TAM domain variant of SOX9 is driving cell autonomous, precocious hypertrophy signaling in chondrocytes. Similar 535 536 alterations in gene regulation have been previously observed in the Sox9 haploinsufficiency 537 mice, where the overall markers of chondrogenesis were inhibited, yet are also coupled with 538 increased expression of markers of hypertrophy and mineralization (23, 56).

539 *Col2a1* is a direct transcriptional target of SOX9 (28), however, *Col2a1* expression was 540 not obviously changed in costal chondrocytes derived from *Sox9^{del/+}* or *Sox9^{del/del}* mice (Figure 541 7E), which is consistent with our analysis of COLII in vivo (Supplemental Figure 4, C-E). We

observed increased Sox9 mRNA level in costal chondrocytes of Sox9^{del/+} and Sox9^{del/del} mice 542 543 compared with that in wild-type cells (Figure 7E), likely the result of SOX9 positive feedback 544 on its expression (57). Despite increased Sox9 transcript levels, we failed to observe any 545 obvious changes in the expression or localization of the SOX9 protein by immunofluorescence 546 or western blotting in primary costal chondrocytes (Figure 7F and Supplemental Figure 8). 547 These results suggest a potential complementation effect driving Sox9 mRNA overexpression 548 in response to the hypomorphic loss of function of the TAM domain microdeletion in SOX9, 549 which was consistent with our previous observations of decreased SOX9 protein stability 550 (Figure 7, A and B).

551 Disturbance in of the TAM domain of SOX9 generates global transcriptional changes in 552 chondrocytes and altered protein expression in spinal tissues

553 Our results show that variants in the TAM domain of SOX9 lead to the compromised formation of the intervertebral discs (Figure 3G and Figure 5L), altered ossification in the endplates 554 555 (Figure 6, M, P and S), and decreased chondrogenesis in cell culture (Figure 7, C-E). All of this 556 data suggests that variants in the TAM domain of SOX9 have a crucial role in the differentiation 557 and maturation of the cartilage lineages. To better understand how the Asp272del variant 558 affects gene regulation, we performed RNA-sequencing analyses on P5 primary costal 559 chondrocytes, a well-accepted source of primary chondrocytes (58, 59). We observed a total of 816 upregulated genes and 452 down-regulated genes in homozygous Sox9^{del/del} compared to 560 heterozygous Sox9^{del/+} mutant mice (Figure 8A and Supplemental Table 3). Gene Ontology 561 562 (GO) enrichment analysis revealed that the differentially expressed genes were strongly related 563 to extracellular matrix (GO:0031012), angiogenesis (GO:0001525), and ossification 564 (GO:0001503) (Supplemental Table 4). Other altered biological processes included connective

tissue development (GO:0061448), cell-substrate adhesion (GO:0031589), and epithelial cell
migration (GO:0010631) (Supplemental Table 4).

567 We observed global alterations in components of the extracellular matrix, including 568 increased expression of Col8a1 (type VIII collagen), Eln (elastin), and Prg4 (proteoglycan 4), 569 and mild upregulation of Coll0a1 (type X collagen) (Figure 8B), which is consistent with our observations of increased Coll0a1/COLX expression in vivo (Figure 6, P-P') and in primary 570 571 chondrocyte culture (Figure 7E). On the contrary, the expression of some fibrotic collagens, 572 including Col3a1 and Col4a1 was significantly reduced (Figure 8B). Additional extracellular 573 matrix components, such as Tnxb (tenascin-X), Tnc (tenascin-C) and Lama2 (laminin subunit 574 alpha 2) were also down-regulated. In addition, several genes involved in angiogenesis such as 575 Vegfa were upregulated. Finally, we observed intriguing results in a class of genes associated 576 with ossification. We found reduced expression of some major markers of ossification, 577 including Collal, Mmp13, and Postn (periostin, osteoblast specific factor), and increased expression of *Timp3* (tissue inhibitor of metalloproteinase 3) (Figure 8B). These results may 578 explain the progressive, high penetrance (93%) of the rib cage deformities in the Sox9^{del/del} mice 579 580 (Figure 6F'), which may be caused by impaired ossification of the rib cage. This dysregulation 581 of genes important for endochondral ossification is also consistent with the loss of endplate 582 ossification observed within the lumbar IVDs of the Sox9^{del/del} mice (Figure 6, M-M'). We also 583 observed increased expression of the bone morphogenetic protein (BMP) and transforming growth factor- β (TGF β) pathways, including *Bmp6*, *Smad5*, and *Tgfbr3*, coupled with up-584 585 regulation of some BMP signaling inhibitors, such as Nog (Noggin) and Grem1 (gremlin, 1 586 DAN family BMP antagonist) (Figure 8B). Collectively, these results show large-scale 587 dysregulation of genes that are important for chondrocyte differentiation and ossification in Sox9^{del/del} mice. 588




Figure 8. The Asp272del TAM domain variant of SOX9 generates global transcriptional changes in chondrocytes and altered protein expression in spinal tissues of the IVD. (A) Volcano plot of RNA-sequencing data generated from P5 primary costal chondrocytes, plotted with Log2 (Fold Change) (X axis) and Log10 (padj)(Y axis, padj<0.05). Several top-changed genes were labeled on the plot. (n=3 replicas for each genotype.) (**B**), A

592 list of candidate genes involved in the top three categories of GO term enrichment analyses. C-H', 593 Immunohistochemistry (IHC) analyses of tenascin X (TNX) and type I collagen (COLI) in P5 tail sections of wild-594 type (C, C' and F, F'), Sox9^{del/+} (D, D' and G, G') and Sox9^{del/del} (E, E' and H, H') mice. TNX expression in 595 connective tissues (red asterisks), inner annulus fibrosus (red arrows), and endplate (yellow arrows) are shown in 596 (C'). Loss of TNX expression in connective tissues is indicated with a black asterisk in (E'). The presence or loss 597 of COLI staining in annulus fibrosus is indicated with red or black asterisks respectively in (F'-H'). (n=6 for each 598 genotype.) I-K, Immunofluorescence (IF) analyses of COLI were performed on P5 mouse tail sections of three 599 different genotypes. (n=6 for each genotype.) L, A model of how SOX9 regulates axial skeleton homeostasis. In 600 a healthy spine, SOX9 maintains normal expression of TNX and COLI in annulus fibrosus, connective tissues and 601 cartilaginous tissues, and precisely controls the expression of COLX in chondrocytes. However, disturbance of 602 SOX9 function results in reduced expression of TNX and COLI in connective tissues and dysregulated expression 603 of COLX in the endplate and growth plate of the spine, which synergistically results in a range of skeletal 604 dysplasia, including intervertebral disc (IVD) deformity, IVD degeneration, and scoliosis. Scale bars: 100µm. VB: 605 vertebral body; CT: connective tissue; EP: endplate; NP: nucleus pulposus; GP-p: proliferative growth plate; 606 GP-h: hypertrophic growth plate; AF-i: inner annulus fibrosus; AF-o: outer annulus fibrosus.

607

In humans, disruption of the TNXB gene (which encodes tenascin-X, TNX, an extracellular 608 609 matrix protein) is associated with Ehlers-Danlos syndrome, which is a connective tissue 610 disorder caused by defective deposition of type I collagen leading to hypermobility of joints 611 and kyphoscoliosis in some patients (60, 61). Since we observed reduced expression of both 612 Tnxb and Collal in primary chondrocyte cultures prior to the onset of scoliosis, we next set 613 out to assay the expression of TNX and COLI in vivo. IHC analyses on P5 wild-type tail 614 sections showed strong TNX expression in the inner annulus fibrosus (Figure 8, C-C', red 615 arrows), a portion of cells in the endplate (Figure 8C', yellow arrows), and the connective 616 tissues surrounding the annulus fibrosus (Figure 8C', red asterisk). However, the expression of TNX was consistently diminished in both Sox9^{del/+} and Sox9^{del/del} mice (Figure 8, D' and E'), 617 with only weak staining in the connective tissues adjacent to IVD in the Sox9^{del/+} mice (Figure 618 619 8D', red asterisk). Similarly, IHC and IF analyses revealed robust COLI expression in the entire 620 annulus fibrosus and adjacent connective tissues of the wild-type mice (Figure 8, F-F', red asterisks; and Figure 8I), which is depleted in both Sox9^{del/+} and Sox9^{del/del} mice (Figure 8, G 621

and H'), with limited expression in the outer annulus fibrosus (Figure 8G', red asterisk; and
Figure 8J-K). Interestingly, the diminished expression of TNX and COLI in annulus fibrosus
overlaps altered SOX9 expression in annulus fibrosus (Figure 3, H''-J'''), suggesting a
regulatory role of SOX9 in maintaining the proper expression of these genes in the IVD.
Altogether, this finding suggests that disturbance of the TAM domain allows for normal
skeletal development to occur but still results in the loss of components, such as TNX and
COLI, that are likely necessary for the maturation and homeostasis of the spine (Figure 8L).

631 **DISCUSSION**

632 Heterozygous mutations in SOX9 cause CMPD, a rare, dominant semi-lethal skeletal disease characterized by congenital shortening and bending of long bones. Most of the variants that 633 634 cause CMPD are non-truncating mutations in HMG and DIM domains or truncating mutations 635 in PQA and TAC domains (31-33). Notably, variants associated with acampomelic CMPD, a 636 subpopulation of CMPD patients that exhibit milder skeletal phenotypes without displaying 637 bending of long bones, are more likely to be either missense mutations of SOX9 or deletions or 638 rearrangements upstream of the SOX9 coding region (34, 38). These observations suggest that 639 locations and the nature of the variants may underlie the severity of CMPD/ acampomilic

640 CMPD.

641 We recently reported a non-truncating pathological variant in the TAC domain which is associated with a milder form of axial skeleton dysplasia (35). Here, we reported the first non-642 643 truncating pathological variant in the TAM domain of SOX9. Patient with this variant exhibit skeletal dysplasia that primarily affects the axial skeleton and is milder than 644 645 CMPD/acampomelic CMPD. Our studies suggest that non-truncating SOX9 variants in the 646 middle (TAM) or C-terminal transactivation domains (TAC) of SOX9 may contribute to 647 skeletal dysplasia that is milder than classic CMPD/acampomelic CMPD, in which they affect primarily or exclusively the axial skeleton. These two studies corroborate with in vitro evidence 648 649 suggest that the two transactivation domains of SOX9 can work synergistically to

650 control the function of SOX9 (8).

Though the function of SOX9 in different skeletal tissues is well studied in mice (23), the molecular, cellular, and developmental abnormalities leading to CMPD/ acampomilic CMPD, especially the milder form of axial skeletal dysplasia, are not well defined, largely due to the lack of human evidence and appropriate animal models (24). In the present study, we analyzed

655 exome sequencing from 424 congenital vertebral malformations cases, a cohort of patients with 656 a broad spectrum of syndromic and non-syndromic vertebral malformations. The inclusion of 657 patients with milder skeletal phenotypes enabled us to identify four novel ultra-rare SOX9 658 variants. We demonstrated that these variants were deleterious and provided acampomelic 659 CMPD diagnosis for two of the patients who carry de novo variants in the HMG domain of 660 SOX9. The identification of these two variants expands the mutational spectrum of SOX9 in 661 acampomelic CMPD and conforms that the hypomorphic SOX9 allele that perturbs its DNA 662 binding ability contributes to acampomelic CMPD. Another variant is in the DIM domain and 663 leads to compromised SOX9 dimerization, which is consistent with previous analyses of DIM 664 domain mutations (19).

For the first time, we identified a missense mutation, Gly276Cys, in the TAM domain of 665 SOX9. The patient carrying this variant exhibited milder phenotypes than that of classical 666 667 CMPD/ acampomelic CMPD, with multiple fusions of the thoracic vertebral and clinodactyly of the distal 5th phalange. Unlike the three variants identified in HMG and DIM domains, the 668 669 mutation in the TAM domain does not obviously affect the transcriptional activity of canonical 670 direct SOX9 targets but leads to reduced protein stability of SOX9. A previous study using 671 cancer cells shows that the SOX9 TAM domain plays an important role in the cellular response 672 to DNA damage. A conserved phosphodegron (CPD) motif locates within the TAM transactivation domain is essential for the binding of FBW7a to SOX9, which is required for 673 674 subsequent ubiquitination and proteasomal destruction of the SOX9 protein (52). Our study 675 confirms that TAM domain is also involved in the regulation of SOX9 stability in chondrogenic 676 lineages, however, the mechanisms of how specific amino acid residues in TAM domain 677 regulate the turnover of SOX9 protein warrants further investigation.

678 Since no non-truncating variants in the TAM domain of SOX9 has been previously 679 reported, we engineered a new mice model ($Sox9^{del/del}$) resulting in an in-frame microdeletion

680 of a single amino acid in the TAM domain (Asp272del), which is four residuals upstream of 681 the human variant (Gly276Cys). Though we were not able to generate the exact human mutation, the Sox9^{del} allele also provides us with valuable information to understand the role of 682 683 the TAM domain in SOX9 function and the etiology of a milder form of axial skeleton 684 dysplasia. In silico analyses show that the Asp272 and Gly276 residues are highly conserved 685 among vertebrate orthologues, and both are predicted to hydrogen bond interact with Asp274 686 to stable a putative helical structure of the SOX9 protein. In addition, the Asp272del variant 687 also shows adequate luciferase activity and reduced protein stability that is comparable with the Glv276Cys variant. We further demonstrate that Sox9^{del} is a hypomorphic allele with the 688 689 genetic complementary experiment over a conditional Sox9 null allele (Sox9^{flox}). These 690 observations suggest that the Sox9^{del} allele may serve as a good genetic mouse model to study 691 the function of the TAM domain and the pathogenesis of milder forms of axial skeletal 692 dysplasia.

693 Interestingly, the homozygous Sox9^{del/del} mutant mice display axial skeleton phenotypes 694 that phenocopy some of the dysplasia observed in the human patient with the Gly276Cys 695 variant, but not in mouse models with typical null or haploinsufficiency of Sox9 (3, 23). For example, the Sox9^{del/del} mutant mice display bending and fusion of some caudal vertebrae 696 without displaying bending of the long bones. The Sox9^{del/del} mutant mice also show loss of 697 698 T13 floating ribs, rib cage dysmorphologies, pathoses of IVD and growth plates, and late-onset scoliosis without congenital vertebral malformations. In contrast, haploinsufficiency of Sox9 699 700 results in more severe forms of skeletal dysplasia and defective cartilage development (14, 23, 701 38). On the other hand, the $Sox9^{del/+}$ mutant mice show much milder skeletal phenotypes 702 compared with Sox9^{del/del} and Sox9 haploinsufficiency mice. All these observations confirm that Sox9^{del} is a mild hypomorphic allele with no dominant-negative impact as reported in other 703 SOX9 truncating variants (24). Though Sox9^{del} does not obviously affect the expression of 704

705 SOX9 protein at the tissue level (Supplemental Figure 8, Western blot of primary chondrocytes) 706 or significantly reduce its transcriptional activity, the function of SOX9 may be compromised 707 by reduced protein stability. Therefore, the hypomorphic Sox9^{del} allele may permit some 708 transcriptional activity at the canonical SOX9 targets and allows for normal skeletal 709 development to occur, however, it may lead to compromised tissue development and maintenance during neonatal and adult development, such as reduced proliferation of the 710 711 endplate in P5 IVD, and reduced proteoglycan staining of the vertebral growth plate in adult 712 mice, which is consistent with the previous finding on the crucial role of SOX9 in disc cell 713 survival and phenotype maintenance, and in the regulation of distinct compartment-specific 714 transcriptomic landscapes (6, 7).

715 Moreover, IHC analysis on tissue sections shows that the expression of SOX9 is reduced 716 in distinct regions of the cartilaginous and connective tissues of the spine (Figure 3, P5 tail). RNA-seq performed on costal chondrocytes at the same age revealed that Sox9^{del} mutation 717 718 causes reduced expression of extracellular matrix components, and alterations in angiogenesis 719 and ossification pathways. SOX9 is known to have a direct role in the establishment of tendon 720 and ligament attachments and indirectly for endochondral ossification (2, 5), thus the role of 721 SOX9 TAM variants on the development and homeostasis of bone and dense connective tissues 722 should be further studied.

One possible mechanism of wedged IVD observed in P5 $Sox9^{de/dell}$ mice is that the altered extracellular matrix components (e.g. abnormally decreased expression of TNX and COLI) lead to altered biomechanical properties of the disc, while the increased expression of type X collagen and dysregulated ossification process within the vertebrae, probably due to the reduced expression of *Col1a1* and *Mmp13* (Figure 8B) and reduced proliferation within the proliferative growth plate (Figure 3Q), synergistically leads to disc deformity (Figure 8L). We also observe signs of disc degeneration in older $Sox9^{de/dell}$ mice, including reduced proteoglycan staining and

730 endplate abnormalities. Our study adds support to previous studies showing that SOX9 is 731 essential for spine development and maintenance of the structural integrity of the spine (3, 6, 732 7, 49). Interestingly, we observed a similar endplate phenotype in another genetic mouse model 733 (Adgrg6 conditional knockout) that was published earlier by our group (62). In Adgrg6 734 conditional mutant mice, we suggest that the endplate-oriented phenotype is a secondary effect due to compromised biomechanical properties of the IVD because of altered expression of 735 736 extracellular matrix components, including reduced expression of SOX9 but increased 737 expression of type X collagen (62, 63). In this study, we observed similar alterations in Sox9^{del/del} mice, where we showed SOX9 expression is regionally reduced, increased expression 738 739 of type X collagen in the endplate and growth plate, supporting a potential synergistic 740 interaction between SOX9 and ADGRG6, which is implicated in adolescent idiopathic scoliosis 741 in humans (64).

742 Taken together, our results demonstrate adult viable skeletal dysplasia phenotypes 743 including scoliosis and malformation of the distal axial skeleton in mice and humans, due to 744 novel pathological mutations localized within the TAM domain of SOX9. Disturbance of the 745 SOX9 TAM domain in mice and in human patient showed axial skeletal malformations without 746 generating more severe skeletal dysplasia and autosomal sex reversal phenotypes, which are 747 commonly associated with known CMPD/ acampomilic CMPD SOX9 mutations in humans. 748 Our study corroborates previous evidence from human and mouse studies that SOX9 has critical 749 roles in axial skeleton formation and adult homeostasis and that SOX9 hypomorphic alleles 750 resulting from variants in the TAM or TAC domain likely underlie skeletal dysplasia that is 751 milder than CMPD/ acampomilic CMPD, which primarily or exclusively affect the axial 752 skeleton. In conclusion, human and mouse variants in SOX9 contribute to a range of skeletal 753 dysplasia dependent on the domain/residual affected, which is suggestive of a general 754 mechanism to be further explored in skeletal dysplasia in humans.

755 MATERIALS AND METHODS

756 Human subjects

A total of 424 probands with congenital vertebral malformations admitted into Peking Union 757 Medical College Hospital (PUMCH) were consecutively enrolled under the framework of the 758 759 Involving Scoliosis and COmorbidities (DISCO) Deciphering disorders study 760 (http://www.discostudy.org/) from 2009 to 2016. Clinical evaluation and exome sequencing were performed as previously described (65). Raw data were processed using the in-house 761 762 developed Peking Union Medical College Hospital Pipeline (PUMP) (65, 66). Ultra-rare 763 variants in SOX9 were selected based on the following criteria: 1) Predicted to alter the protein 764 sequence; 2) Either arising de novo or absent from the public databases such as the genome 765 aggregation database (gnomAD, https://gnomad.broadinstitute.org/). Patients carrying 766 candidate variants in SOX9 are reported in this study.

767 Sanger sequencing

For human patients and mouse models, candidate variants in *SOX9/Sox9* were validated by Sanger sequencing. For human patients, variant-encoding amplicons were amplified by PCR from genomic DNA obtained from probands and parents from trios (Supplemental Table 1). The amplicons were purified using an Axygen AP-GX-50 kit (lot no. 05915KE1) and sequenced by Sanger sequencing on an ABI3730XL instrument.

773 Construction of SOX9 expression constructs and Cos-7 cell culture

Full-length wild-type SOX9 and SOX9 with variants were cloned into the pEGFP-C1 expression
vector (Catalog #6084-1, Takara Bio Company). Cos-7 cells were obtained from the Institute
of Basic Medical Sciences, Chinese Academy of Medical Sciences (Beijing, China). The cells

777 were cultured in DMEM medium (Gibco) supplemented with 10% fetal bovine serum (Gibco),

penicillin (50 U/ml, Life Technology), and streptomycin (50 µg/ml, Life Technology).

779 Electrophoretic mobility shift assay

780 Electrophoretic mobility shift assay (EMSA) was used to detect the binding affinity of SOX9 781 proteins to the conical SOX9 binging motifs as previously described with modifications (19). 782 Biotin-labeled DNA probes were designed based on two canonical SOX9 binding motifs 783 derived from an enhancer region of the mouse Coll1a2 gene, named Coll1a2 B/C and D/E 784 respectively, according to the original publication (19). The sequences of these motifs are listed 785 in Supplemental Table 2. Cos-7 cells were transfected with the SOX9 expression constructs or 786 GFP control construct for 48 hours. The expression level of wild-type and various SOX9 787 mutant proteins was quantified by Western blot before the experiment and equal amounts of SOX9 were detected (Supplemental Figure 2). After 48 hours, the whole-cell lysates were 788 789 extracted and incubated with 0.5 µl of Biotin-labeled probe (1000fM) for 20 min on ice in a 790 15µl reaction system as described previously (19), using Poly (dI:dC) as the unspecific 791 competitor. The 150-fold unlabeled DNA probes (150X) were incubated with cell lysate of 792 Cos-7 cells transfected with wild-type SOX9 protein. Samples were loaded onto native 6.5% 793 polyacrylamide gel and electrophoresed in 0.5xTBE at 180V for 1 h. The gel was transferred 794 to a nylon membrane at 100V for 30 min. The biotin-labeled DNA probes transferred to the 795 membrane were cross-linked for 10 min with a hand-held UV lamp and detected by 796 Chemiluminescence (BioRad, TY8836).

797 Luciferase assay

Luciferase assay was performed with a luciferase reporter (*Coll1a2*-Luc) and various *SOX9* expression constructs in Cos-7 cell cultures. To generate the *Coll1a2*-Luc reporter, four tandem copies of a canonical SOX9 binding motif derived from an enhancer region of the

801 mouse Coll1a2 gene (named Coll1a2 D/E) (19) was cloned into the luciferase reporter vector 802 pGL3Basic (Promega E1751). The sequence of this motif is listed in Supplemental Table 2. 803 Full-length wild-type SOX9 and SOX9 with variants were cloned into the pEGFP-C1 804 expression vector (Catalog #6084-1, Takara Bio Company). These overexpression constructs 805 were transfected into the Cos-7 cell line for 48 hours and equal amounts of protein were 806 harvested for Western Blotting analysis of SOX9. No obvious difference in SOX9 expression 807 was observed among wild-type and different SOX9 variants (Supplemental Figure 3, A and B). 808 A standard curve was generated to determine the linear range of the SOX9-mediated reporter 809 transactivation and to optimize the reaction system (Supplemental Figure 3C). For each 810 independent experiment, Cos-7 cells were transfected with 400ng of Coll1a2-Luc reporter 811 plasmids, 50ng of various SOX9-expression vectors, and 5ng of Renilla luciferase control 812 reporter vectors. Cells were harvested 48h post-transfection for immediate luciferase activity 813 analysis using the Promega Dual-Luciferase Reporter Assay System (Promega E1910). The 814 Firefly luciferase activity was normalized to the Renilla luciferase activity. Three independent 815 experiments were performed with reproducible results.

816 Half-life measurement

817 The half-life of wild-type and variant SOX9 proteins were evaluated using a cycloheximide 818 (CHX) chase assay. Cos-7 cells were seeded into 6-well plates in DMEM containing 10% FBS 819 and transfected with 2 µg of various SOX9 expression constructs. 48 hours later, Cos-7 cells 820 were treated with 80 µg/ml of CHX and were harvested at 0h, 1h, 2h, 4h, and 6h after treatment. 821 Cells were dissolved in absolute ethanol and harvested in ice-cold phosphate-buffered saline 822 (PBS, pH 7.4) by centrifuging at 2500 × g for 2 min at 4 °C. Cell pellets were lysed in RIPA 823 lysis and extraction buffer (Thermo Scientific) and sonicated for 3×5 s on ice. Total protein 824 from the cell lysate was quantitated using the Pierce BCA protein assay kit (Thermo Scientific) 825 and analyzed by the standard Western blot assay. The membrane was blotted with a primary

anti-GFP tag antibody (Cell Signaling Technology, 2956T, 1:1000) and detected with a
secondary horseradish peroxidase-conjugated antibody (ab7090; Abcam; 1:5000).
Quantification of band intensity was conducted using Image Lab (BioRad). Three independent
experiments were performed with reproducible results.

830 Generation of mouse models

The *Sox9* ^{Asp272del} mutant mouse was fortuitously isolated after pronuclear injection using an oligo-dependent gene editing approach using a single CRISPR synthetic guide RNA 5'-GTTCACCGATGTCCACGTCG-3' (Synthego) mixed with Alt-R S.p. HiFi Cas9 Nuclease V3 protein (IDT, 1081060). For gene editing, a donor oligonucleotide 5'-

835 TCTGGCAGAGGGGGGGGCAGACAGCCCCCCATCGACTTtCGtGAtGTaGAtATCtGcG

AACTGAGCAGCGACGTCATCTCCAACATTGAGACCTT-3', with phosphorothioate 836 837 linkages between the first three and last three nucleotides, was used to induce a specific edit to model the Gly276Cys human mutation and add synonymous changes to include an EcoRV 838 839 restriction site for genotyping. The pronuclear injection was performed by the Mouse Genetic 840 Engineering Facility (UT-MGEF) at the University of Texas at Austin using standard protocols 841 (https://www.biomedsupport.utexas.edu/transgenics). Of the 123 implanted embryos from two 842 independent sessions, 3 mice were isolated at sexual maturity. Of these, 1 founder male transmitted the Sox9 Asp272del allele. Locus-specific genotyping of the Sox9 Asp272del mutation was 843 844 performed using PCR primers 5'-GTCTTTCTCTTTTATGGCCTGC-3' and 845 5'TGGCAAGTATTGGTCAAACTCA-3', followed by Sanger sequencing confirmation. Heterozygous Sox9 Asp272del mutant mice are maintained in the C57B6/J background and have 846 847 been outcrossed to the C57BL/6J strain for over 10 generations. At each cross, we observe a 848 100% correspondence between genotype and phenotype.

849 Analysis of mouse tissues

855

Radiographs of the mouse skeleton were generated using a Kubtec DIGIMUS X-ray system (Kubtec T0081B) with auto exposure under 25 kV. All radiographs were taken immediately after the mice were euthanized to avoid the stiffness of the skeleton. Cobb's angle was measured on high-resolution X-ray images with the software Surgimap (https://www.surgimap.com), as previously described by (46). Measures of the length of the spine (T1-L6) and long bone (femur)

were performed on high-resolution X-ray images with ImageJ (https://imagej.nih.gov/ij/).

856 Mouse spine or tail tissues were harvested at P5, P60, and 6 months of age. Histological 857 analysis was performed on the distal tail or lumbar (L3-L5) spines fixed in 10% neutral buffered 858 formalin for 3 days at room temperature, followed by 3-5 days of decalcification in Formic 859 Acid Bone Decalcifier (Immunocal, StatLab). After decalcification, bones were embedded in 860 paraffin and sectioned at 5µm thickness. Alcian Blue Hematoxylin/Orange G (ABH/OG) 861 staining was performed following standard protocols (Center for Musculoskeletal Research, University of Rochester). Immunohistochemical (IHC) analyses were performed on paraffin 862 863 sections with traditional antigen retrieval (COLII and COLX: 4 mg/ml pepsin in 0.01 N HCl 864 solution, 37°C water bath for10 min; SOX9 and Collagen I: 10 µg/ml proteinase K in 1x PBS, room temperature for 10 min; TNX: 10 mM Tris-EDTA with 0.05% Triton-X-100, pH 9.0, 865 866 75°C water bath for 5 min) and colorimetric developed development methodologies with the following primary antibodies: anti-SOX9 (EMD Millipore AB5535, 1:200), anti-COLII 867 (Thermo Scientific MS235B, 1:100), anti-COLX (Quarteet, 1-CO097-05, 1:200), anti-COLI 868 869 (Abcam, ab138492, 1:1000), and anti-TNX (Santa Cruz Biotechnology sc-271594, 1:100). 870 Immunofluorescence (IF) staining was performed on paraffin sections as previously described 871 with modifications (67). Briefly, paraffin sections of P5 mouse tails were de-paraffinized and 872 incubated with 10 µg/ml proteinase K in 1x PBS at room temperature for 10 min. Sections were

washed in 1xPBST and incubated with primary antibodies: anti-SOX9 (Chemicon AB5535, 1:200) and anti-TNX (Santa Cruz Biotechnology sc-271594, 1:100), and developed with secondary antibody Alexa Flour 488 Goat anti Rabbit (A11034, 1:1500). Images were taken using a Keyence BZ-X710 all-in-One fluorescence microscope and a Nikon Ti2E/CSU-W1 spinning disc confocal system. Quantification of SOX9 (+) cells was performed on high resolution SOX9 IHC staining images with ImageJ. At least two sections were analyzed for each mouse. At least three mice for each genotype were analyzed.

880 MicroCT analysis

881 MicroCT analysis was performed on the tails of P60 mice and P1 mouse pups. All samples 882 were fixed in 10% neutral-buffered formalin for 3 days at room temperature, thoroughly 883 washed, and scanned on a Bruker SkyScan 1276 (Bruker Corporation, Billerica, 884 Massachusetts). The tails were scanned at 50 kV and 200 µA with a 0.25 mm Al filter, with a 885 3 µm voxel size. The mouse pups were first proceeded for Alcian Blue/Alizarin Red skeletal 886 stain using standard acid-alcohol conditions and cleared in 1% KOH and Glycerol. These 887 embryos were scanned in glycerol at 50 kV and 100 µA with a 0.5 mm Al filter, with a 3 µm 888 voxel size. 3D Rendering and analysis was done using Bruker CTVox and CTAn software.

889 Costal chondrocytes isolation and maturation

Murine costal chondrocytes were isolated as previously described by (67) with modifications. Briefly, anterior rib cages and sterna were isolated from 5-day-old wild-type, $Sox9^{del/+}$ and $Sox9^{del/del}$ pups with the soft tissue removed. Rib cages were digested in 2mg/ml Pronase (Roche) solution at 37°C for 1 hour with constant agitation, followed by 1-hour digestion in 3mg/ml collagenase D (Roche) solution in high-glucose Dulbecco's modified Eagle's medium (DMEM, Gibco) at 37°C. The rib cages were then transferred into a petri dish and digested in collagenase D (3 mg/ml in high-glucose DMEM) for 4 to 6 hours. Murine costal chondrocyte

897 cell suspensions were filtered through 40µm filters and seeded at a density of 200,000 cells per 898 well in 24-well tissue culture plates. Cells were maturated with maturation medium 899 [highglucose DMEM supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, 900 and 50µg/ml ascorbic acid (Sigma, A4403)] for 10 days with changing of the medium in every 901 two days. After 10 days of maturation, cells were fixed with 500µl of 10% Formaldehyde at RT for 20min, thoroughly washed with PBS, and incubated with Alcian Blue staining solution 902 903 (Sigma, B8438) or anti-SOX9 antibody (EMD Millipore AB5535, 1:400) overnight at room 904 temperature or 4°C. The next day Alcian Blue stained cells were washed with deionized water 905 and air-dried overnight. The SOX9 antibody-stained cells were developed with a secondary 906 antibody Alexa Flour 488 Goat anti Rabbit (A11034, 1:1500).

907 RNA isolation and real-time RT-PCR

908 RNA was isolated from primary costal chondrocytes without maturation with a QIAGEN 909 RNeasy mini kit (QIAGEN 74104). Reverse transcription was performed using 500 ng total 910 RNA with an iScript cDNA synthesis kit (Bio-Rad 1708840). Real-time RT-PCR (qPCR) 911 analyses were performed as previously described by (67). Gene expression was normalized to 912 b-actin mRNA and relative expression was calculated using the 2-($\Delta\Delta$ Ct) method. The mouse-913 specific primers were used to quantify gene expression (Supplemental Table 1). Real-time RT-914 PCR efficiency was optimized and melting curve analyses of products were performed to 915 ensure reaction specificity.

916 **Protein extraction and western blot of the primary cells**

917 Total proteins were extracted from primary costal chondrocytes without maturation with
918 protein extraction buffer [50mM HEPES, 1.5mM EDTA (pH 8.0), 150mM NaCl, 10%
919 glycerol, 1% Triton X-100] supplemented with protease and phosphatase inhibitors (Roche).
920 10mg of protein from each sample was resolved by 4–15% SDS-polyacrylamide gel

electrophoresis and transferred to the nitrocellulose membranes. Western blots were then
blocked with LI-COR blocking buffer and incubated overnight with primary antibodies antiSOX9 (EMD Millipore AB5535, 1:1000) and anti-GAPDH (Cell Signaling, #2118, 1:2500) at
4°C with gentle rocking. The next day western blots were detected with the LI-COR Odyssey
infrared imaging system. Quantification of band intensity was conducted with ImageJ. Three
independent experiments were performed with reproducible results.

927 RNA-sequencing and data analysis

928 RNA-sequencing was performed on costal chondrocytes isolated from P5 *Sox9^{del/+}* mice and 929 *Sox9^{del/del}* mice. Briefly, anterior rib cages and sterna were isolated from P5 pups, digested in 930 2mg/ml Pronase solution at 37°C for 1 hour with constant agitation, followed by 1-hour 931 digestion in 3mg/ml collagenase D solution in 1XPBS. Cells were disassociated, thoroughly 932 washed in 1XPBS and filtered through a 40µm cell strainer. Cells were pelleted by centrifuging 933 at 300 × g for 4 min at room temperature. RNA was isolated with a QIAGEN RNeasy mini kit 934 (QIAGEN 74104).

935 Library preparation, RNA sequencing, and bioinformatics analysis were performed by 936 Novogene Co., Ltd. Messenger RNA was purified from total RNA using poly-T oligo-attached 937 magnetic beads. After fragmentation, the first strand of cDNA was synthesized using random 938 hexamer primers, followed by the second strand of cDNA synthesis. The library was examined 939 with Qubit and real-time PCR for quantification and a bioanalyzer for size distribution 940 detection. Quantified libraries were pooled and sequenced on Illumina platforms and pairedend 941 reads were generated. Raw data in fastq format were firstly processed through in-house Perl 942 scripts and clean reads were obtained. Reference genome and gene model annotation files were 943 downloaded from the genome website directly. Index of the reference genome was built using 944 Hisat2 v2.0.5 and paired-end clean reads were aligned to the reference genome using Hisat2

945 v2.0.5. featureCounts v1.5.0-p3 was used to count the reads numbers mapped to each gene. 946 FPKM of each gene was calculated based on the length of the gene and the reads count mapped 947 to this gene. Differential expression analysis was performed using the DESeq2 R package 948 (1.20.0). The resulting P-values were adjusted using Benjamini and Hochberg's approach for 949 controlling the false discovery rate. Genes with an adjusted P-value ≤ 0.05 found by DESeq2 were assigned as differentially expressed. Gene Ontology (GO) enrichment analysis of 950 951 differentially expressed genes was implemented by the clusterProfiler R package, in which gene 952 length bias was corrected. GO terms with corrected P value less than 0.05 were considered 953 significantly enriched in differential expressed genes.

954 Statistics

955 Statistical analyses were performed in GraphPad Prism 9.1.2 (GraphPad Software Inc, 956 SanDiego, CA) or SPSS version 15.0 (SPSS). For luciferase assay, half-life analysis, Cobb 957 angle, and gene expression analysis to compare two or more experimental groups, 2-tailed 958 Student's t-test and Welch one-way ANOVA followed by Turkey's multiple comparison test 959 were applied when appropriate. A p-value of less than 0.05 is considered statistically 960 significant.

961

962 Study approval

963 This study was approved by the Institutional Review Board of Peking Union Medical College

964 Hospital (JS-2364). Written informed consent was obtained from each patient or legal

965 guardian of the patient. All mouse studies and procedures were approved by the Animal

966 Studies Committee at the University of Texas at Austin.

968 Statement

The patient ID is a unique research identifier that cannot be linked back to the original patients outside of the research group. Medical history details have also been removed to protect the patients' privacy.

972

973 Data availability

974 Data are available from the corresponding author upon reasonable request.

975 Author contributions

976 N.W., R.S.G., L.W., Z.L. and S.Z. conceptualized the project. L.W., Z.L., S.Z. L.Z., Xiaoxin.L., N.W. and R.S.G. designed the study. L.W., S.Z., Z.L., C.Q., B.T., G.H., R.S.G. L.L. Xinyu.L. 977 978 and L.Z. performed the experiments. S.Z., L.W., Z.L., K.X., C.M.K, Xiaoxin.L., R.S.G., H.G. 979 and L.L. validated the data. N.W., S.Z., L.W., Z.L., H.G., S.Y., V.A., S.M., S.W., Y.N., R.S.G. 980 and T.J.Z. analyzed the data. L.W., S.Z., Z.L., K.X., N.W. and R.S.G. wrote the manuscript. 981 S.Z., Z.L., L.W., K.X., N.W., Z.W., C.Q., Xinyu.L. and R.S.G. critically revised the 982 manuscript. Z.L., R.S.G., N.W. and Z.W. supervised the work. All authors have read and 983 approved the final submitted manuscript. The first authorship is shared by Z.L., L.W., S.Z., and 984 K.X. The order was determined based on their respective contributions and efforts to the study. 985

986 Acknowledgments

We thank Dr. Yunjia Wang at the Department of Spine and Orthopaedics in Xiangya
Hospital/Central South University, and Ms. Karagan Day at the Department of Pediatrics in
Dell Medical School of the University of Texas at Austin for their supporting work in mouse

- 990 husbandry and X-ray image taking. We also thank Nanjing Geneseeq Technology Inc. for the
- 991 technical help in sequencing and Ekitech Technology Inc. for the technical support in database
- 992 and data management.

994 Funding

- 995 This research was funded in part by the National Natural Science Foundation of China
- 996 (81930068 to Z.W., 2102522 to L.W., 82072391 to N.W., 881972037 and 82172382 to J.Z.,
- and 81874022 and 82172483 to X.L.), Beijing Natural Science Foundation (JQ20032 to N.W.),
- 998 CAMS Innovation Fund for Medical Sciences (CIFMS, 2021-I2M-1-051 to J.Z. and N.W.,
- 999 2021-I2M-1-052 to Z.W., 2020-I2M-C&T-B-030 to J.Z.), National High Level Hospital
- 1000 Clinical Research Funding (2022-PUMCH-D-007 to J.Z. and N.W., 2022-PUMCH-C-033 to
- 1001 N.W.), National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National
- 1002 Institutes of Health under Award (R01AR072009 to R.S.G., K99AR077090 to Z.L.), Shandong
- 1003 Natural Science Foundation (ZR202102210113 to L.W.), and the Non-profit Central Research
- 1004 Institute Fund of Chinese Academy of Medical Sciences (No. 2019PT320025 to N.W.).

1005

1007 SUPPLEMENTAL FIGURE LEGENDS

Supplemental Figure 1. The 3D structures of SOX9 are predicted by AlphaFold. (A) A model of human SOX9 was built by AlphaFold (htts://alphafold.ebi.ac.uk/). (B) Ile73 is predicted to be important for stabilizing alpha-helical interactions. (C) Met113 is predicted to stabilize alpha-helical interactions through a single hydrogen bond with Gln117 and two hydrogen bonds with Aan110. (D) Ala133 is predicted to stabilize alpha-helical interactions by a hydrogen bond with Ser136. (E) Gly276 is predicted to hydrogen bond with Asp274. Asp272 is also predicted to hydrogen bond with Asp274 by stabilizing an alpha-helical structure.

1015

1016 Supplemental Figure 2. Equal amounts of SOX9 proteins were used for the EMSA assay.

1017 (A) Western blotting of anti-GFP was performed on total protein extracted from blank Cos-7 1018 cells (Blank), Cos-7 cells transfected with empty EGFP expression vectors (Control), wild-1019 type SOX9 (WT), or Ile73Thr, Met113Leu, and Ala133Gly SOX9 variants that were cloned 1020 into the EGFP expression vectors at 48 hours post-transfection. GAPDH is used as a loading 1021 control. No obvious changes in expression were observed among wild-type and variant SOX9 1022 proteins. (B) Quantification analysis shows that comparable amounts of SOX9 were detected 1023 among wild-type and various SOX9 variant proteins. Bars are plotted with mean and SD. Each 1024 dot represents one experiment analyzed. The statistical difference is evaluated by one-way 1025 ANOVA followed by Tukey's multiple comparison test. ns: not significant. (n=3 experiments.) 1026

1020

Supplemental Figure 3. Optimization of the luciferase assay. (A) Western blotting was performed on total protein extracted from blank Cos-7 cells (Blank), Cos-7 cells transfected with wild-type SOX9 construct (Wild type), or Ile73Thr, Gly276Cys, Met113Leu, Ala133Gly, and Asp276Del SOX9 variants at 48 hours post-transfection. GAPDH is used as a loading

1031 control. No obvious changes in expression were observed among wild-type and variant SOX9 1032 proteins. (B) Quantification analysis shows that comparable amounts of SOX9 were detected 1033 among wild-type and various SOX9 variant proteins. Bars are plotted with mean and SD. Each 1034 dot represents one experiment analyzed. The statistical difference is evaluated by one-way 1035 ANOVA followed by Tukey's multiple comparison test. ns: not significant. (n=3 experiments.) 1036 (C) A standard curve was generated to optimize the transfection dose for the luciferase assays. 1037 SOX9-expression plasmids were diluted to a gradient of concentration with the final amount 1038 from 10⁻⁴ to 10⁶ ng. Relative luciferase activity was normalized to the Renilla internal control. 1039 The linear range of the SOX9-mediated reporter transactivation is between 1ng-100ng. 50ng 1040 of SOX9-expression plasmids was selected for luciferase assays shown in Figure 2B. n=3 1041 experiments.

1042

Supplemental Figure 4. Expression of extracellular matrix components in P5 mouse tail 1043 1044 sections. (A-B") Representative Alcian Blue Hematoxylin /Orange G (ABH/OG) staining 1045 (AA'') and IHC staining of SOX9 (B-B'') on unwedged IVD in tail sections of P5 Sox9del/del 1046 mutant mice. The endplate is indicated with a dot line and a vertical bar in (\mathbf{A}') and (\mathbf{B}') . The 1047 boundary between inner and outer annulus fibrosus is indicated with a dot-line in (A'') and 1048 (B''). (n=3.) C-H, IHC analysis of COLII (C-E) and COLX (F-H) on tail sections of P5 wildtype, $Sox9^{del/+}$, and $Sox9^{del/del}$ mice. n=3 for each genotype. Scale bars: 100µm. EP: 1049 1050 endplate; GP-p: proliferative growth plate; GP-h: hypertrophic growth plate; AF-i: inner 1051 annulus fibrosus; AF-o: outer annulus fibrosus.

1052

1053 Supplemental Figure 5. Assessment of skeletal development in *Sox9* loss of function 1054 mutant mice. (A-C) Representative skeletal preps of Cre(-) wild-type (A), heterozygous

1055 *Col2a1-Cre; Sox9^{flox/+}* mutant (**B**), and compound heterozygous *Col2a1-Cre; Sox9^{flox/del}* mutant

- 1056 mice (C) at P1. (D-F) Representative MicroCT images of Cre(-) wild-type (D), heterozygous
- 1057 *Col2a1-Cre; Sox9^{flox/+}* mutant (E), and compound heterozygous *Col2a1-Cre; Sox9^{flox/del}* mutant
- 1058 mice (\mathbf{F}) at P1. n=4 for each genotype. Scale bar: 1mm.
- 1059

1060 Supplemental Figure 6. Young adult *Sox9*^{del/del} mice display mild rib cage deformities.

- 1061 (A-C) Representative sagittal X-ray images of wild-type (A), $Sox9^{del/+}$ (B), and $Sox9^{del/del}$ mice
- 1062 (C) at P60. Red arrows indicate the curvature of the distal ribs (C). n=4 for wild-type mice; 2
- 1063 males, 2 females. n=8 for Sox9^{del/+} mice; 5 males, 3 females. n=7 for Sox9^{del/del} mice; 4 males,
- 1064 3 females. Scale bar: 10mm.
- 1065

1066 Supplemental Figure 7. Mature adult Sox9^{del/del} mice display rib cage deformities and 1067 impaired ossification in the endplate of the intervertebral discs. (A-E) Additional sagittal X-ray images of wild-type (A), $Sox9^{del/+}$ (B), and $Sox9^{del/del}$ mice (C-E) at 6 months. Red arrows 1068 1069 indicate the bending of the sternums (B-D) or the curvature of the distal ribs I. (F-J') Additional ABH/OG staining of lumbar IVDs (L3/4 or L4/5) of wild-type (F, F'), Sox9^{del/+} (G, G') and 1070 Sox9^{del/del} (H-J') mice at 6 months. Wild-type and Sox9^{del/+} mice consistently showed 1071 1072 ossification within the endplate at 6 months (yellow arrows, F' and G'). On the contrary, 1073 Sox9^{del/del} mice showed reduced endplate ossification (yellow arrow, J') or persistency of 1074 hypertrophic chondrocyte-like cells within the endplate (yellow asterisks, H', I'). n=3 for each 1075 genotype. Scale bars: 10mm in A; 100µm in F-F'. AF: annulus fibrosus; EP: endplate; GP: 1076 growth plate; NP: nucleus pulposus.

1077

1078 Supplemental Figure 8. SOX9 protein expression in costal chondrocytes. (A)
1079 Representative Western blot image of SOX9 performed on P5 costal chondrocytes isolated

- 1080 from three different genotypes of mice. GAPDH is used as a loading control (n=3 experiments).
- 1081 (B) Quantification analysis shows that comparable amounts of SOX9 protein were detected
- 1082 among three genotypes. Bars are plotted with mean and 95%CI. Each dot represents one
- 1083 experiment analyzed. The statistical difference is evaluated by one-way ANOVA followed by
- 1084 Tukey's multiple comparison test. ns: not significant (n=3 experiments).
- 1085
- Supplemental Table 1. Primers used for amplification of the DNA segments containing the
 candidate *SOX9* variants and for RT-PCR quantification.
- 1088 Supplemental Table 2. Sequences of the SOX9 binding motifs used for EMSA and luciferase1089 assay.
- Supplemental Table 3. Differential gene expression analysis of primary costal chondrocytes
 derived from Sox9^{del/+} and Sox9^{del/del} mutant mice.
- 1092 Supplemental Table 4. GO-terms associated with differential gene expression analysis of
- 1093 primary costal chondrocytes derived from *Sox9*^{*del/+*} and *Sox9*^{*del/del*} mutant mice.

1095 **Table 1.** Clinical and genetic features of the four probands

ID	RDD2003P0397	SCO2003P0412	SCO2003P0060	SCO2003P1898
Variant information	1			
HGVS	c.337A>C	c.398C>G	c.218T>C	c.826G>T
	(p.Met113Leu)	(p.Ala133Gly)	(p.Ile73Thr)	(p.Gly276Cys)
Origin	de novo	Unknown	de novo	de novo
Domain	HMG	HMG	DIM	ТАМ
CADD	27.3	26.5	24.1	29.6
Skeleton, joints and limbs				
Scoliosis	-	+	+	+
Kyphosis	+	-	+	-
Lordosis	+	-	-	-
Vertebral	Fusion of	L2 wedged	T6 wedged	Fusion of
malformation	cervical vertebrae	vertebra	vertebra	thoracic
				vertebrae
Other skeletal	Hypoplastic	Brachydactyly	Hypoplastic	Spinal bifida
deformity	scapulae		scapulae, Short	occulta,
			stature	Clinodactyly

1097 Abbreviations: DIM: dimerization domain; HMG: high mobility group domain; TAM:

1098 transactivation middle domain.

1100 **REFERENCES**

- Lefebvre V. Roles and regulation of SOX transcription factors in skeletogenesis. *Curr Top Dev Biol.* 2019;133:171-93.
- Lefebvre V, and Dvir-Ginzberg M. SOX9 and the many facets of its regulation in the
 chondrocyte lineage. *Connect Tissue Res.* 2017;58(1):2-14.
- Akiyama H, Chaboissier MC, Martin JF, Schedl A, and de Crombrugghe B. The
 transcription factor Sox9 has essential roles in successive steps of the chondrocyte
 differentiation pathway and is required for expression of Sox5 and Sox6. *Genes Dev.*2002;16(21):2813-28.
- Barrionuevo F, Taketo MM, Scherer G, and Kispert A. Sox9 is required for notochord
 maintenance in mice. *Dev Biol.* 2006;295(1):128-40.
- Sugimoto Y, Takimoto A, Akiyama H, Kist R, Scherer G, Nakamura T, et al.
 Scx+/Sox9+ progenitors contribute to the establishment of the junction between
 cartilage and tendon/ligament. *Development*. 2013;140(11):2280-8.
- Henry SP, Liang S, Akdemir KC, and de Crombrugghe B. The postnatal role of Sox9
 in cartilage. *J Bone Miner Res.* 2012;27(12):2511-25.
- Tsingas M, Ottone OK, Haseeb A, Barve RA, Shapiro IM, Lefebvre V, et al. Sox9
 deletion causes severe intervertebral disc degeneration characterized by apoptosis,
 matrix remodeling, and compartment-specific transcriptomic changes. *Matrix Biol.*2020;94:110-33.
- Haseeb A, and Lefebvre V. The SOXE transcription factors-SOX8, SOX9 and SOX10share a bi-partite transactivation mechanism. *Nucleic Acids Res.* 2019;47(13):6917-31.
- 1122 9. Oh CD, Maity SN, Lu JF, Zhang J, Liang S, Coustry F, et al. Identification of SOX9
- interaction sites in the genome of chondrocytes. *PLoS One*. 2010;5(4):e10113.

1124	10.	Barrionuevo F, and Scherer G. SOX E genes: SOX9 and SOX8 in mammalian testis
1125		development. Int J Biochem Cell Biol. 2010;42(3):433-6.
1126	11.	Zhao L, Li G, and Zhou GQ. SOX9 directly binds CREB as a novel synergism with the
1127		PKA pathway in BMP-2-induced osteochondrogenic differentiation. J Bone Miner Res.
1128		2009;24(5):826-36.
1129	12.	Miyake A, Kou I, Takahashi Y, Johnson TA, Ogura Y, Dai J, et al. Identification of a
1130		susceptibility locus for severe adolescent idiopathic scoliosis on chromosome 17q24.3.
1131		PLoS One. 2013;8(9):e72802.
1132	13.	Takeda K, Kou I, Otomo N, Grauers A, Fan YH, Ogura Y, et al. A multiethnic meta-
1133		analysis defined the association of rs12946942 with severe adolescent idiopathic
1134		scoliosis. J Hum Genet. 2019;64(5):493-8.
1135	14.	Wagner T, Wirth J, Meyer J, Zabel B, Held M, Zimmer J, et al. Autosomal sex reversal
1136		and campomelic dysplasia are caused by mutations in and around the SRY-related gene
1137		SOX9. Cell. 1994;79(6):1111-20.
1138	15.	Foster JW, Dominguez-Steglich MA, Guioli S, Kwok C, Weller PA, Stevanovic M, et
1139		al. Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-
1140		related gene. Nature. 1994;372(6506):525-30.
1141	16.	Houston CS, Opitz JM, Spranger JW, Macpherson RI, Reed MH, Gilbert EF, et al. The
1142		campomelic syndrome: review, report of 17 cases, and follow-up on the currently 17-
1143		year-old boy first reported by Maroteaux et al in 1971. Am J Med Genet. 1983;15(1):3-
1144		28.
1145	17.	Bernard P, Tang P, Liu S, Dewing P, Harley VR, and Vilain E. Dimerization of SOX9
1146		is required for chondrogenesis, but not for sex determination. Hum Mol Genet.
1147		2003;12(14):1755-65.

- 1148 18. Lewandoski M, Meyers EN, and Martin GR. Analysis of Fgf8 gene function in
 vertebrate development. *Cold Spring Harb Symp Quant Biol.* 1997;62:159-68.
- 1150 19. Sock E, Pagon RA, Keymolen K, Lissens W, Wegner M, and Scherer G. Loss of DNA-

dependent dimerization of the transcription factor SOX9 as a cause for campomelic

1152 dysplasia. *Hum Mol Genet*. 2003;12(12):1439-47.

1151

- Leipoldt M, Erdel M, Bien-Willner GA, Smyk M, Theurl M, Yatsenko SA, et al. Two
 novel translocation breakpoints upstream of SOX9 define borders of the proximal and
 distal breakpoint cluster region in campomelic dysplasia. *Clin Genet*. 2007;71(1):6775.
- 1157 21. Velagaleti GV, Bien-Willner GA, Northup JK, Lockhart LH, Hawkins JC, Jalal SM, et
 al. Position effects due to chromosome breakpoints that map approximately 900 Kb
 upstream and approximately 1.3 Mb downstream of SOX9 in two patients with
 campomelic dysplasia. *Am J Hum Genet*. 2005;76(4):652-62.
- Pfeifer D, Kist R, Dewar K, Devon K, Lander ES, Birren B, et al. Campomelic
 dysplasia translocation breakpoints are scattered over 1 Mb proximal to SOX9:
 evidence for an extended control region. *Am J Hum Genet*. 1999;65(1):111-24.
- Bi W, Huang W, Whitworth DJ, Deng JM, Zhang Z, Behringer RR, et al.
 Haploinsufficiency of Sox9 results in defective cartilage primordia and premature
 skeletal mineralization. *Proc Natl Acad Sci U S A*. 2001;98(12):6698-703.
- Au TYK, Yip RKH, Wynn SL, Tan TY, Fu A, Geng YH, et al. Hypomorphic and
 dominant-negative impact of truncated SOX9 dysregulates Hedgehog-Wnt signaling,
 causing campomelia. *Proc Natl Acad Sci U S A*. 2023;120(1):e2208623119.
- 1170 25. Macpherson RI, Skinner SA, and Donnenfeld AE. Acampomelic campomelic
 1171 dysplasia. *Pediatr Radiol.* 1989;20(1-2):90-3.

- von Bohlen AE, Bohm J, Pop R, Johnson DS, Tolmie J, Stucker R, et al. A mutation
 creating an upstream initiation codon in the SOX9 5' UTR causes acampomelic
 campomelic dysplasia. *Mol Genet Genomic Med.* 2017;5(3):261-8.
- 1175 27. Vivekanandan S, Moovarkumudalvan B, Lescar J, and Kolatkar PR. Crystallization and
- 1176 X-ray diffraction analysis of the HMG domain of the chondrogenesis master regulator
- Sox9 in complex with a ChIP-Seq-identified DNA element. *Acta Crystallogr F Struct Biol Commun.* 2015;71(Pt 11):1437-41.
- 1179 28. Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S, Ling KW, et al. SOX9 directly
 1180 regulates the type-II collagen gene. *Nat Genet*. 1997;16(2):174-8.
- 118129.Lefebvre V, Zhou G, Mukhopadhyay K, Smith CN, Zhang Z, Eberspaecher H, et al.1182An 18-base-pair sequence in the mouse proalpha1(II) collagen gene is sufficient for1183expression in cartilage and binds nuclear proteins that are selectively expressed in
- 1184 chondrocytes. *Mol Cell Biol.* 1996;16(8):4512-23.
- Bridgewater LC, Lefebvre V, and de Crombrugghe B. Chondrocyte-specific enhancer
 elements in the Coll1a2 gene resemble the Col2a1 tissue-specific enhancer. *J Biol Chem.* 1998;273(24):14998-5006.
- 1188 31. McDowall S, Argentaro A, Ranganathan S, Weller P, Mertin S, Mansour S, et al.
- Functional and structural studies of wild type SOX9 and mutations causing campomelic
 dysplasia. *J Biol Chem.* 1999;274(34):24023-30.
- 1191 32. Csukasi F, Duran I, Zhang W, Martin JH, Barad M, Bamshad M, et al. Dominant1192 negative SOX9 mutations in campomelic dysplasia. *Hum Mutat*. 2019;40(12):2344-52.
- Schock EN, and LaBonne C. Sorting Sox: Diverse Roles for Sox Transcription Factors
 During Neural Crest and Craniofacial Development. *Front Physiol.* 2020;11:606889.
- 1195 34. Unger S, Scherer G, and Superti-Furga A. In: Adam MP, Everman DB, Mirzaa GM,
- 1196 Pagon RA, Wallace SE, Bean LJH, et al. eds. *GeneReviews((R))*. Seattle (WA); 1993.

- Wu N, Wang L, Hu J, Zhao S, Liu B, Li Y, et al. A Recurrent Rare SOX9 Variant
 (M469V) is Associated with Congenital Vertebral Malformations. *Curr Gene Ther.*2019;19(4):242-7.
- 1200 36. Calvache CA, Vasquez EC, Romero VI, Hosomichi K, and Pozo JC. Novel SRY-box
 1201 transcription factor 9 variant in campomelic dysplasia and the location of missense and
 1202 nonsense variants along the protein domains: A case report. *Front Pediatr.*1203 2022;10:975947.
- 37. Geraldo MT, Valente GT, Nakajima RT, and Martins C. Dimerization and
 Transactivation Domains as Candidates for Functional Modulation and Diversity of
 Sox9. *PLoS One*. 2016;11(5):e0156199.
- 38. Staffler A, Hammel M, Wahlbuhl M, Bidlingmaier C, Flemmer AW, Pagel P, et al.
 Heterozygous SOX9 mutations allowing for residual DNA-binding and transcriptional
 activation lead to the acampomelic variant of campomelic dysplasia. *Hum Mutat.*2010;31(6):E1436-44.
- Wada Y, Nishimura G, Nagai T, Sawai H, Yoshikata M, Miyagawa S, et al. Mutation
 analysis of SOX9 and single copy number variant analysis of the upstream region in
 eight patients with campomelic dysplasia and acampomelic campomelic dysplasia. *Am J Med Genet A*. 2009;149A(12):2882-5.
- 1215 40. Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, et al. Clinical
 1216 application of whole-exome sequencing across clinical indications. *Genet Med.*1217 2016;18(7):696-704.
- 1218 41. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and
 1219 guidelines for the interpretation of sequence variants: a joint consensus
 1220 recommendation of the American College of Medical Genetics and Genomics and the
 1221 Association for Molecular Pathology. *Genet Med.* 2015;17(5):405-24.

Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly
accurate protein structure prediction with AlphaFold. *Nature*. 2021;596(7873):583-9.

- Huang YH, Jankowski A, Cheah KS, Prabhakar S, and Jauch R. SOXE transcription
 factors form selective dimers on non-compact DNA motifs through multifaceted
 interactions between dimerization and high-mobility group domains. *Sci Rep.*2015;5:10398.
- Herdgewater LC, Walker MD, Miller GC, Ellison TA, Holsinger LD, Potter JL, et al.
 Adjacent DNA sequences modulate Sox9 transcriptional activation at paired Sox sites
 in three chondrocyte-specific enhancer elements. *Nucleic Acids Res.* 2003;31(5):154153.
- Giampietro PF, Raggio CL, Blank RD, McCarty C, Broeckel U, and Pickart MA.
 Clinical, genetic and environmental factors associated with congenital vertebral
 malformations. *Mol Syndromol.* 2013;4(1-2):94-105.
- 1235 46. Cobb JR. Scoliosis; quo vadis. *J Bone Joint Surg Am.* 1958;40-A(3):507-10.
- 47. Abid I, Ewais MM, Marranca J, and Jaroszewski DE. Pectus Excavatum: A Review of
 Diagnosis and Current Treatment Options. *J Am Osteopath Assoc.* 2017;117(2):1061238 13.
- 1239 48. David VL. Current Concepts in the Etiology and Pathogenesis of Pectus Excavatum in
 1240 Humans-A Systematic Review. *J Clin Med.* 2022;11(5).
- Haseeb A, Kc R, Angelozzi M, de Charleroy C, Rux D, Tower RJ, et al. SOX9 keeps
 growth plates and articular cartilage healthy by inhibiting chondrocyte
 dedifferentiation/osteoblastic redifferentiation. *Proc Natl Acad Sci US A*. 2021;118(8).
- Smith LJ, Nerurkar NL, Choi KS, Harfe BD, and Elliott DM. Degeneration and
 regeneration of the intervertebral disc: lessons from development. *Dis Model Mech.*2011;4(1):31-41.

- 1247 51. Zhao CQ, Wang LM, Jiang LS, and Dai LY. The cell biology of intervertebral disc
 1248 aging and degeneration. *Ageing Res Rev.* 2007;6(3):247-61.
- 1249 52. Hong X, Liu W, Song R, Shah JJ, Feng X, Tsang CK, et al. SOX9 is targeted for
 1250 proteasomal degradation by the E3 ligase FBW7 in response to DNA damage. *Nucleic*1251 *Acids Res.* 2016;44(18):8855-69.
- Schneider-Poetsch T, Ju J, Eyler DE, Dang Y, Bhat S, Merrick WC, et al. Inhibition of
 eukaryotic translation elongation by cycloheximide and lactimidomycin. *Nat Chem Biol.* 2010;6(3):209-17.
- 1255 54. Ghosh S, Laha M, Mondal S, Sengupta S, and Kaplan DL. In vitro model of
 1256 mesenchymal condensation during chondrogenic development. *Biomaterials*.
 1257 2009;30(33):6530-40.
- 1258 55. Hu G, Codina M, and Fisher S. Multiple enhancers associated with ACAN suggest
 highly redundant transcriptional regulation in cartilage. *Matrix Biol.* 2012;31(6):3281260 37.
- 1261 56. Leung VY, Gao B, Leung KK, Melhado IG, Wynn SL, Au TY, et al. SOX9 governs
 1262 differentiation stage-specific gene expression in growth plate chondrocytes via direct
 1263 concomitant transactivation and repression. *PLoS Genet*. 2011;7(11):e1002356.
- Sekido R, and Lovell-Badge R. Sex determination involves synergistic action of SRY
 and SF1 on a specific Sox9 enhancer. *Nature*. 2008;453(7197):930-4.
- 1266 58. Taniguchi Y, Kawata M, Ho Chang S, Mori D, Okada K, Kobayashi H, et al. Regulation
 1267 of Chondrocyte Survival in Mouse Articular Cartilage by p63. *Arthritis Rheumatol.*1268 2017;69(3):598-609.
- 1269 59. Nishimori S, Lai F, Shiraishi M, Kobayashi T, Kozhemyakina E, Yao TP, et al. PTHrP
 1270 targets HDAC4 and HDAC5 to repress chondrocyte hypertrophy. *JCI Insight*.
 1271 2019;4(5).

- Burch GH, Gong Y, Liu W, Dettman RW, Curry CJ, Smith L, et al. Tenascin-X
 deficiency is associated with Ehlers-Danlos syndrome. *Nat Genet*. 1997;17(1):104-8.
- Mao JR, Taylor G, Dean WB, Wagner DR, Afzal V, Lotz JC, et al. Tenascin-X
 deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen
 deposition. *Nat Genet.* 2002;30(4):421-5.
- Liu Z, Easson GWD, Zhao J, Makki N, Ahituv N, Hilton MJ, et al. Dysregulation of
 STAT3 signaling is associated with endplate-oriented herniations of the intervertebral
 disc in Adgrg6 mutant mice. *PLoS Genet*. 2019;15(10):e1008096.
- 1280 63. Liu Z, Hussien AA, Wang Y, Heckmann T, Gonzalez R, Karner CM, et al. An adhesion
 1281 G protein-coupled receptor is required in cartilaginous and dense connective tissues to
 1282 maintain spine alignment. *Elife*. 2021;10.
- Kou I, Takahashi Y, Johnson TA, Takahashi A, Guo L, Dai J, et al. Genetic variants in
 GPR126 are associated with adolescent idiopathic scoliosis. *Nat Genet*.
 2013;45(6):676-9.
- 1286 65. Zhao S, Zhang Y, Chen W, Li W, Wang S, Wang L, et al. Diagnostic yield and clinical
 1287 impact of exome sequencing in early-onset scoliosis (EOS). *J Med Genet*.
 1288 2021;58(1):41-7.
- 1289 66. Chen N, Zhao S, Jolly A, Wang L, Pan H, Yuan J, et al. Perturbations of genes essential
 1290 for Mullerian duct and Wolffian duct development in Mayer-Rokitansky-Kuster1291 Hauser syndrome. *Am J Hum Genet.* 2021;108(2):337-45.
- 1292 67. Liu Z, Chen J, Mirando AJ, Wang C, Zuscik MJ, O'Keefe RJ, et al. A dual role for
 1293 NOTCH signaling in joint cartilage maintenance and osteoarthritis. *Sci Signal*.
 1294 2015;8(386):ra71.

1295